<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cells</journal-id>
<journal-id journal-id-type="iso-abbrev">Cells</journal-id>
<journal-id journal-id-type="publisher-id">cells</journal-id>
<journal-title-group>
<journal-title>Cells</journal-title>
</journal-title-group>
<issn pub-type="epub">2073-4409</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30884855</article-id>
<article-id pub-id-type="pmc">6468615</article-id>
<article-id pub-id-type="doi">10.3390/cells8030255</article-id>
<article-id pub-id-type="publisher-id">cells-08-00255</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Prieto-Dominguez</surname>
<given-names>Néstor</given-names>
</name>
<xref ref-type="aff" rid="af1-cells-08-00255">1</xref>
<xref ref-type="aff" rid="af2-cells-08-00255">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parnell</surname>
<given-names>Christopher</given-names>
</name>
<xref ref-type="aff" rid="af3-cells-08-00255">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1856-7289</contrib-id>
<name>
<surname>Teng</surname>
<given-names>Yong</given-names>
</name>
<xref ref-type="aff" rid="af1-cells-08-00255">1</xref>
<xref ref-type="aff" rid="af3-cells-08-00255">3</xref>
<xref ref-type="aff" rid="af4-cells-08-00255">4</xref>
<xref ref-type="corresp" rid="c1-cells-08-00255">*</xref>
</contrib>
</contrib-group>
<aff id="af1-cells-08-00255"><label>1</label>Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, GA 30912, USA; <email>nprid@unileon.es</email></aff>
<aff id="af2-cells-08-00255"><label>2</label>Institute of Biomedicine (IBIOMED), University of León, 24010 León, Spain</aff>
<aff id="af3-cells-08-00255"><label>3</label>Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; <email>CPARNELL@augusta.edu</email></aff>
<aff id="af4-cells-08-00255"><label>4</label>Department of Medical laboratory, Imaging and Radiologic Sciences, College of Allied Health, Augusta University, Augusta, GA 30912, USA</aff>
<author-notes>
<corresp id="c1-cells-08-00255"><label>*</label>Correspondence: <email>yteng@augusta.edu</email>; Tel.: +1-706-446-5611; Fax: +1-706-721-9415</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2019</year>
</pub-date>
<volume>8</volume>
<issue>3</issue>
<elocation-id>255</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Small GTPases are a family of low molecular weight GTP-hydrolyzing enzymes that cycle between an inactive state when bound to GDP and an active state when associated to GTP. Small GTPases regulate key cellular processes (e.g., cell differentiation, proliferation, and motility) as well as subcellular events (e.g., vesicle trafficking), making them key participants in a great array of pathophysiological processes. Indeed, the dysfunction and deregulation of certain small GTPases, such as the members of the Ras and Arf subfamilies, have been related with the promotion and progression of cancer. Therefore, the development of inhibitors that target dysfunctional small GTPases could represent a potential therapeutic strategy for cancer treatment. This review covers the basic biochemical mechanisms and the diverse functions of small GTPases in cancer. We also discuss the strategies and challenges of inhibiting the activity of these enzymes and delve into new approaches that offer opportunities to target them in cancer therapy.</p>
</abstract>
<kwd-group>
<kwd>small GTPases</kwd>
<kwd>Arf1</kwd>
<kwd>inhibitors</kwd>
<kwd>cancer therapy</kwd>
<kwd>anticancer</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-cells-08-00255" sec-type="intro">
<title>1. Introduction</title>
<p>Small GTPases are a large family of hydrolases that bind and hydrolyze GTP to GDP in order to regulate many cellular activities (e.g., cell differentiation, proliferation, and motility) [<xref ref-type="bibr" rid="B1-cells-08-00255">1</xref>]. Inherently, small GTPases have a basal mild endogenous GTPase activity that is dependent on Mg<sup>2+</sup> to weaken the bond between the last two phosphates in GTP in order to form GDP [<xref ref-type="bibr" rid="B2-cells-08-00255">2</xref>,<xref ref-type="bibr" rid="B3-cells-08-00255">3</xref>,<xref ref-type="bibr" rid="B4-cells-08-00255">4</xref>]. Small GTPases are normally maintained in an GDP-bound inactive state and are induced by guanine-nucleotide exchange factors (GEFs), which replace the GDP molecule that normally occupies the small GTPase binding pocket with GTP [<xref ref-type="bibr" rid="B4-cells-08-00255">4</xref>]. Equally important for the regulation of small GTPases are the GTPase-activating proteins (GAPs), which deactivate small GTPases through enhancing their endogenous hydrolytic activity, leading to the shifting of GTP to GDP and their subsequent inactivation [<xref ref-type="bibr" rid="B4-cells-08-00255">4</xref>].</p>
<p>Small GTPases have been grouped into five major classes according to their sequence homology and on their physiological functions [<xref ref-type="bibr" rid="B3-cells-08-00255">3</xref>]: Arf subfamily, Ras subfamily, Ras-homolog (Rho) subfamily, Ras-related in brain (Rab) subfamily, and Ras-related nuclear protein (Ran) subfamily [<xref ref-type="bibr" rid="B5-cells-08-00255">5</xref>,<xref ref-type="bibr" rid="B6-cells-08-00255">6</xref>]. However, the Ran and the Rab subfamilies have recently been fused due to the high homology that presents their components [<xref ref-type="bibr" rid="B7-cells-08-00255">7</xref>].</p>
<p>The Arf subfamily is involved in a broad spectrum of physiological roles, such as the organization of the cytoskeleton, the sorting of vesicle cargo, the recruitment of vesicle coat proteins, and the alteration of lipid membranes through the recruitment of key enzymes, including phosphatidylinositol-four-phosphate adapter protein 1 (FAPP1), FAPP2, and the ceramide transfer protein (CERT) (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B8-cells-08-00255">8</xref>,<xref ref-type="bibr" rid="B9-cells-08-00255">9</xref>]. The Arf subfamily consists of 6 Arf isoforms, 22 different Arf-like proteins (ARL) and Sar1 [<xref ref-type="bibr" rid="B8-cells-08-00255">8</xref>,<xref ref-type="bibr" rid="B10-cells-08-00255">10</xref>]. Deregulation of some Arf isoforms has been shown to induce cancer formation and progression by enhancing cell proliferation through the activation of mitogen-activated protein kinases (MAPK) and ribosomal protein S6 kinase beta-1 (p70S6K) [<xref ref-type="bibr" rid="B11-cells-08-00255">11</xref>,<xref ref-type="bibr" rid="B12-cells-08-00255">12</xref>]. Furthermore, deregulation of certain Arf family members, such as Arf1 and Arf6, enhances cancer cell invasion and metastasis by stimulating Ras-related C3 botulinum toxin substrate 1 (Rac1), paxillin, talin or focal adhesion kinase (FAK) [<xref ref-type="bibr" rid="B12-cells-08-00255">12</xref>,<xref ref-type="bibr" rid="B13-cells-08-00255">13</xref>,<xref ref-type="bibr" rid="B14-cells-08-00255">14</xref>].</p>
<p>The Ras subfamily includes 36 different members divided into seven subgroups: Ras proteins, Ras-related proteins (RRAS), Ras-like proteins (Ral), Ras-proximal proteins (Rap), Ras-related associated with diabetes (Rad) and Gem-related proteins (GRE), Ras homolog enriched in brain (Rheb), and Ras-like in all tissues proteins (Rit) [<xref ref-type="bibr" rid="B7-cells-08-00255">7</xref>,<xref ref-type="bibr" rid="B15-cells-08-00255">15</xref>]. The members of the Ras subfamily are involved in the activation of intracellular signaling networks, resulting in enhancing cellular proliferation, adhesion, migration, and survival, as well as in limiting apoptosis (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B15-cells-08-00255">15</xref>]. Ras overexpression has been found in more than 15% of human tumors [<xref ref-type="bibr" rid="B15-cells-08-00255">15</xref>], since its upregulation can promote cancer cell proliferation by the deregulation of the basal activation levels of the MAPK, phosphatidylinositol 3-kinase (PI3K), and phospholipase C epsilon (PLCε) pathways [<xref ref-type="bibr" rid="B15-cells-08-00255">15</xref>]. In addition, Ral overexpression stimulates tumorigenesis and tumor invasion in a Ras-dependent manner due to its ability to induce cell exocytosis by interacting with Sec5 and the exocyst complex component 84 (Exo84) [<xref ref-type="bibr" rid="B16-cells-08-00255">16</xref>]. The upregulation of certain Rap members can also promote cancer cell proliferation, migration and invasion due to their capability to alter integrin-mediated cell adhesion [<xref ref-type="bibr" rid="B17-cells-08-00255">17</xref>,<xref ref-type="bibr" rid="B18-cells-08-00255">18</xref>]. Rheb proteins promote carcinogenic cell proliferation and tumorigenesis by promoting the activation of the mechanistic target of rapamycin complex 1 (mTORC1) [<xref ref-type="bibr" rid="B19-cells-08-00255">19</xref>]. Finally, Rit proteins enhance neuronal survival and differentiation, thus their deregulation could be associated with neuronal tumor progression and with the onset of many nervous system pathologies, such as Parkinson’s disease, autism, or schizophrenia [<xref ref-type="bibr" rid="B20-cells-08-00255">20</xref>].</p>
<p>The Rho family consists of 22 proteins divided into seven subgroups: Ras-related C3 botulinum toxin substrate (Rac), Rho-related proteins (RhoA), cell division control protein 42 homolog (Cdc42), TC10 and T-cell leukemia/lymphoma protein 1A (TCL), Rho-related GTP-binding protein Rho6 precursor (Rnd), Rho-related BTB domain-containing protein (RhoBTB) and [<xref ref-type="bibr" rid="B21-cells-08-00255">21</xref>,<xref ref-type="bibr" rid="B22-cells-08-00255">22</xref>]. The members of the Rho family are involved in controlling actin turnover and in coordinating cell shape and movement through the regulation of the activity of the actomyosin complex (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B23-cells-08-00255">23</xref>]. More in detail, Rho subfamily proteins can generate different actin structures to allow the displacement of the cell in response to several mechanical stimuli, such as Rac-dependent filamentous-actin-rich lamellipodia or Cdc42-dependent filopodia protrusions (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B21-cells-08-00255">21</xref>,<xref ref-type="bibr" rid="B22-cells-08-00255">22</xref>]. On the other hand, the aberrant expression of several small GTPases of this family, such as Rac, Cdc42 and RhoA, in carcinogenic cells enhances cancer promotion and progression by facilitating cell cycle progression and mitosis, disrupting tight cellular junctions that prevent cell mobility and inducing epithelial to mesenchymal transition (EMT) to enhance the formation of secondary tumors [<xref ref-type="bibr" rid="B21-cells-08-00255">21</xref>,<xref ref-type="bibr" rid="B22-cells-08-00255">22</xref>]. Moreover, RhoA and RhoC can also promote the formation of new vessels towards the carcinogenic mass through inducing the release of several proangiogenic factors, such as vascular endothelial grown factor [<xref ref-type="bibr" rid="B21-cells-08-00255">21</xref>].</p>
<p>The Rab family consists of approximately 70 members whose main function is to manage vesicular trafficking between intracellular organelles (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B24-cells-08-00255">24</xref>]. The Rab family members select and collect vesicle cargo by increasing the affinity of certain protein sorting receptors, such as the mannose-6-phosphate receptor (M6PR), to the nascent vesicle (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B25-cells-08-00255">25</xref>]. These small GTPases modulate vesicle transport through actin filaments and microtubules by recruiting, respectively, myosin V and kinesins (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B25-cells-08-00255">25</xref>]. Additionally, they induce vesicle fusion by interacting with certain members of the NSF-attachment protein receptors (SNAREs) family that tether the transport vacuole to the acceptor membrane (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B25-cells-08-00255">25</xref>]. The upregulation of certain members of the Rab family (such as Rab25, Rab5 and Rab11) in carcinogenic cells induces tumorigenesis by increasing cell proliferation and migration, via the activation of the Akt/mTORC1, extracellular signal-regulated kinase 1 (ERK1), and Wnt/β-catenin pathways, as well as inhibits tumor cell apoptosis via the decrease of Bak and Bax expression [<xref ref-type="bibr" rid="B24-cells-08-00255">24</xref>,<xref ref-type="bibr" rid="B26-cells-08-00255">26</xref>].</p>
<p>Ran controls molecular export and import from the nucleus to the cytoplasm. Ran GEFs, which activate Ran, accumulate in the nucleus and their interaction with Ran allows the binding and transfer of the cargo from the nucleus to the cytoplasm (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B27-cells-08-00255">27</xref>]. Once in the cytoplasm, the active Ran-GTPs are inhibited by their Ran GAPs, which are located in the cytoplasm, generating this distinct compartmentation of the Ran GEFs and Ran GAPs. The Ran-activation gradient between these two compartments is responsible for nuclear molecular exporting (<xref ref-type="fig" rid="cells-08-00255-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B27-cells-08-00255">27</xref>,<xref ref-type="bibr" rid="B28-cells-08-00255">28</xref>]. Besides, more recent studies have demonstrated that Ran-activation gradient could be indispensable for nuclear import, since its disruption impedes the entrance of large proteins inside the nucleus [<xref ref-type="bibr" rid="B29-cells-08-00255">29</xref>]. Otherwise, Ran can also modulate the assembly of mitotic spindles that control chromosome spatial organization during cell division [<xref ref-type="bibr" rid="B30-cells-08-00255">30</xref>]. It has recently been claimed that Ran overexpression improves cancer aggressiveness by promoting tumor proliferation, progression and metastasis [<xref ref-type="bibr" rid="B31-cells-08-00255">31</xref>]. Therefore, the development of certain molecules that reduce its expression and activation in carcinogenic cells could prevent cell proliferation by disturbing mitotic spindle formation, leading to promote their death by apoptosis [<xref ref-type="bibr" rid="B31-cells-08-00255">31</xref>].</p>
<p>The outer mitochondrial membrane GTPase Miro, which contains four EF hands and two GTPase domains [<xref ref-type="bibr" rid="B32-cells-08-00255">32</xref>], enables the distribution of mitochondria within the cell due to its ability to associate with the kinesin heavy chain [<xref ref-type="bibr" rid="B33-cells-08-00255">33</xref>]. Besides, other studies have recently suggested that the Miro EF domains act as Ca<sup>2+</sup> sensors, increasing the mitochondrial uptake of this ion [<xref ref-type="bibr" rid="B33-cells-08-00255">33</xref>].</p>
<p>Therefore, the development of small GTPase inhibitors could be a useful new treatment strategy for both non-carcinogenic and carcinogenic diseases [<xref ref-type="bibr" rid="B34-cells-08-00255">34</xref>]. However, the generation of these inhibitors is a challenging issue owing to the fine regulatory roles assigned to each of the members of the small GTPases protein family (<xref ref-type="fig" rid="cells-08-00255-f002">Figure 2</xref>) [<xref ref-type="bibr" rid="B34-cells-08-00255">34</xref>,<xref ref-type="bibr" rid="B35-cells-08-00255">35</xref>]. Possible mechanisms by which new inhibitors can be designed include the development of molecules that prevent the formation of the specific GEF-GTPases complex, the impairment of the binding of GTP to GTPases, the increase of GAP protein activity to reduce the pool of active small GTPases, the blocking of the transduction of the activation signal to their specific downstream effector and the inhibition of their membrane-binding domain (<xref ref-type="fig" rid="cells-08-00255-f002">Figure 2</xref>) [<xref ref-type="bibr" rid="B34-cells-08-00255">34</xref>,<xref ref-type="bibr" rid="B36-cells-08-00255">36</xref>].</p>
</sec>
<sec id="sec2-cells-08-00255">
<title>2. Arf1 and Its Inhibitors in Cancer Therapy</title>
<p>Arf1 overexpression stimulates tumor progression and invasion, thus the inhibition of this protein could be useful for restraining cancer progression [<xref ref-type="bibr" rid="B12-cells-08-00255">12</xref>]. The inhibitors that are currently available to block this protein are listed in <xref ref-type="table" rid="cells-08-00255-t001">Table 1</xref></p>
<p>For instance, LM11 can abolish Arf1 activation by inhibiting its association in the Golgi apparatus with its specific GEF, Arf nucleotide-binding site opener (ARNO) [<xref ref-type="bibr" rid="B37-cells-08-00255">37</xref>,<xref ref-type="bibr" rid="B38-cells-08-00255">38</xref>]. The high specificity of LM11 to Arf1 ensures that it does not abrogate other analogs, such as Arf6, making it suitable to treat Arf1-overexpressing tumors [<xref ref-type="bibr" rid="B37-cells-08-00255">37</xref>]. For instance, the treatment of breast tumors that overexpress Arf1 with LM11 reduces their aggressiveness by decreasing cell proliferation and invasion, as well as by inducing apoptosis [<xref ref-type="bibr" rid="B13-cells-08-00255">13</xref>,<xref ref-type="bibr" rid="B38-cells-08-00255">38</xref>]. Furthermore, LM11 disrupts breast cancer adhesion to the extracellular matrix by inhibiting paxillin translocation to the cell membrane [<xref ref-type="bibr" rid="B13-cells-08-00255">13</xref>], which is essential to connect integrins with the actin cytoskeleton [<xref ref-type="bibr" rid="B39-cells-08-00255">39</xref>]. Curiously, LM11 seems to be ineffective when tumor cells carry a K38A substitution in Arf1 [<xref ref-type="bibr" rid="B37-cells-08-00255">37</xref>], thus it is essential that Arf1 overexpressing tumors be tested for variants before the use of this inhibitor.</p>
<p>The Arf1 inhibitor Exo2 prevents the activation of certain Arf1-specific GEF enzymes by binding to their Sec7 domain [<xref ref-type="bibr" rid="B40-cells-08-00255">40</xref>]. This inhibition impedes the release of secretory vesicles from the endoplasmic reticulum (ER) to the Golgi apparatus [<xref ref-type="bibr" rid="B41-cells-08-00255">41</xref>,<xref ref-type="bibr" rid="B42-cells-08-00255">42</xref>], as well as reduces cellular lipid storage by inhibiting perilipin-2 expression [<xref ref-type="bibr" rid="B43-cells-08-00255">43</xref>]. Besides, this molecule presents high specificity for vesicle cargo since it impedes the retrograde transport of the Shiga toxin from the early endosomes to the ER, but does not hinder cholera toxin transport between the same compartments [<xref ref-type="bibr" rid="B42-cells-08-00255">42</xref>]. On the other hand, our research group reveals that Exo2 has the potential to reduce prostate tumor growth and metastasis through inhibiting Arf1-mediated ERK1/2 activation [<xref ref-type="bibr" rid="B44-cells-08-00255">44</xref>]. Most recently, we showed for the first time that active GTP-bound Arf1 is much higher in metastatic head and neck squamous cell carcinoma (HNSCC) cells compared with their paired non-metastatic cells, supporting the critical role of Arf1 activation in HNSCC metastasis [<xref ref-type="bibr" rid="B45-cells-08-00255">45</xref>]. We further provided evidence that EGF induces HNSCC cell invasion through the EGFR-Arf1 signaling complex and interrupting it using Exo2 or histone deacetylase inhibitor TSA deters the progression of HNSCC, providing a rational basis for Arf1-targeted anti-HNSCC therapy [<xref ref-type="bibr" rid="B45-cells-08-00255">45</xref>].</p>
<p>Brefeldin A (BFA) is a lactone-derived compound isolated from <italic>Eupenicillium brefeldianum</italic> that impairs Arf1 activation by hindering its association with its GEF enzyme [<xref ref-type="bibr" rid="B46-cells-08-00255">46</xref>,<xref ref-type="bibr" rid="B47-cells-08-00255">47</xref>]. The 7-hydroxyl residue of BFA seems to be essential to this process because its loss disrupts its affinity for the Arf1-GEF complex, preventing its inhibitory action [<xref ref-type="bibr" rid="B48-cells-08-00255">48</xref>]. This molecule can reduce anaplastic large cell lymphoma proliferation through reducing Arf1-dependent signal transducer and activator of transcription 3 (STAT3) phosphorylation [<xref ref-type="bibr" rid="B49-cells-08-00255">49</xref>]. It also presents a slight cytotoxic activity in other types of cancers, such as in lung, colorectal, ovarian, breast, prostate, melanoma or central nervous system [<xref ref-type="bibr" rid="B50-cells-08-00255">50</xref>]. Nevertheless, BFA shows poor bioavailability and high toxicity while exhibiting a number of pleiotropic effects in non-target organs, preventing the development of phase 1 clinical trials [<xref ref-type="bibr" rid="B42-cells-08-00255">42</xref>,<xref ref-type="bibr" rid="B49-cells-08-00255">49</xref>,<xref ref-type="bibr" rid="B51-cells-08-00255">51</xref>]. Therefore, the generation of new chemical derivatives of BFA with higher anticarcinogenic activity and lower off-target effects is essential to improve its use in cancer therapy [<xref ref-type="bibr" rid="B50-cells-08-00255">50</xref>,<xref ref-type="bibr" rid="B51-cells-08-00255">51</xref>]. For instance, acetylated BFA derivatives can reduce the viability of esophagus squamous cell carcinoma cells in a 500-times greater manner than native BFA [<xref ref-type="bibr" rid="B51-cells-08-00255">51</xref>]. Furthermore, ester BFA derivatives present higher potency than native BFA against different cancer types, which ultimately can reduce their off-target effects by lowering administered doses [<xref ref-type="bibr" rid="B50-cells-08-00255">50</xref>]. Finally, the addition of vinyl or aromatic groups to the C<sub>15</sub> of BFA increases its ability to reduce HeLa cell proliferation [<xref ref-type="bibr" rid="B52-cells-08-00255">52</xref>].</p>
<p>AMF-26, also known as M-COPA, which was isolated from some species of the <italic>Trichoderma</italic> genus, also impairs the formation of the Arf1-GEF complex by disrupting GEF activity [<xref ref-type="bibr" rid="B47-cells-08-00255">47</xref>,<xref ref-type="bibr" rid="B53-cells-08-00255">53</xref>,<xref ref-type="bibr" rid="B54-cells-08-00255">54</xref>]. This molecule has greater bioavailability than BFA, increasing its feasibility for being used in cancer treatment [<xref ref-type="bibr" rid="B54-cells-08-00255">54</xref>]. In fact, AMF-26 can induce complete tumor regression in breast cancer xenografts [<xref ref-type="bibr" rid="B54-cells-08-00255">54</xref>], reduce the proliferation of 39 different cancers in a variety of human organs (such as breast, colon, kidney, skin, central nervous system, lung, ovary, and stomach) [<xref ref-type="bibr" rid="B53-cells-08-00255">53</xref>,<xref ref-type="bibr" rid="B55-cells-08-00255">55</xref>], as well as diminish angiogenesis through suppressing the activation of the vascular endothelial growth factor receptor 1/2 (VEGFR1/2) and the nuclear factor-κB (NF-κB) pathways [<xref ref-type="bibr" rid="B56-cells-08-00255">56</xref>]. In addition, AMF-26 deactivates a mutant form of the endolysosomal Kit, leading to sensitizing carcinogenic mast cell to imatinib [<xref ref-type="bibr" rid="B57-cells-08-00255">57</xref>]. Finally, AMF-26 also prevents Shiga toxin-dependent apoptosis by decreasing its translocation into the Golgi apparatus [<xref ref-type="bibr" rid="B58-cells-08-00255">58</xref>].</p>
<p>Sec7 inhibitor H3 (SecinH3) is a non-specific Arf inhibitor, which abrogates both Arf6 and Arf1 signaling by binding and inhibiting the Sec7 catalytic domain of ARNO and deactivating cytohesins, which are small ARF-specific GEFs [<xref ref-type="bibr" rid="B59-cells-08-00255">59</xref>,<xref ref-type="bibr" rid="B60-cells-08-00255">60</xref>]. SecinH3 was firstly developed to analyze the harmful effects that insulin resistance generates in human cells, since Arf6 down-regulation hinders insulin response in hepatic cells [<xref ref-type="bibr" rid="B60-cells-08-00255">60</xref>] and impairs glucose-stimulated insulin secretion in pancreatic β cells [<xref ref-type="bibr" rid="B61-cells-08-00255">61</xref>]. Moreover, this inhibitor can also reduce <italic>Salmonella enterica</italic> invasion by decreasing the Arf-activated pool [<xref ref-type="bibr" rid="B62-cells-08-00255">62</xref>]. Otherwise, this inhibitor presents great therapeutic effects in some carcinogenic diseases. For example, it diminishes the growth of breast xenografts and reduces breast-related lung metastasis and tumor aggressiveness [<xref ref-type="bibr" rid="B63-cells-08-00255">63</xref>]. Furthermore, it can also reduce the proliferation of certain non-small-cell lung cancer cell types by decreasing epithelial growth factor receptor (EGFR) activation and inducing apoptosis in both in vivo and in vitro models [<xref ref-type="bibr" rid="B64-cells-08-00255">64</xref>]. These beneficial effects ultimately reduce non-small-cell lung cancer resistance to gefitinib [<xref ref-type="bibr" rid="B64-cells-08-00255">64</xref>]. Finally, SecinH3 abolishes the migration, invasion, and proliferation of colorectal cancer cells in both in vivo and in vitro models [<xref ref-type="bibr" rid="B65-cells-08-00255">65</xref>].</p>
<p>M69, which is a RNA aptamer (an oligonucleotide that recognizes and attaches to a specific target with high affinity) [<xref ref-type="bibr" rid="B66-cells-08-00255">66</xref>], can impede Arf effects by deactivating GEF enzymes through binding to their catalytic Sec7 domain [<xref ref-type="bibr" rid="B67-cells-08-00255">67</xref>]. Although few experiments have been currently done with this inhibitor, it seems to present anti-carcinogenic effects as its expression in T lymphocytes leads to the reorganization of their actin cytoskeleton and to decreasing their adhesion to the extracellular matrix [<xref ref-type="bibr" rid="B67-cells-08-00255">67</xref>].</p>
</sec>
<sec id="sec3-cells-08-00255">
<title>3. Ras and Its Inhibitors in Cancer Therapy</title>
<p>The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers, stimulating intensive effort in developing anti-Ras inhibitors in order to get them to the clinic (<xref ref-type="table" rid="cells-08-00255-t002">Table 2</xref>). However, there is no effective Ras inhibitor to be used for cancer treatment [<xref ref-type="bibr" rid="B35-cells-08-00255">35</xref>,<xref ref-type="bibr" rid="B68-cells-08-00255">68</xref>]. Therefore, other chemical and biological strategies should be developed to accomplish the inhibition of this small GTPase.</p>
<sec id="sec3dot1-cells-08-00255">
<title>3.1. Chemical Strategies for Suppressing Ras Activity</title>
<p>Ras has a flat tertiary structure, which does not provide clear sites where small repressing ligands can bind, apart from its nucleotide binding site [<xref ref-type="bibr" rid="B69-cells-08-00255">69</xref>]. The picomolar affinity of Ras for GTP allows for this GTPase to be activated when the concentration of this nucleotide is low [<xref ref-type="bibr" rid="B70-cells-08-00255">70</xref>]. These two properties are responsible for the clinical failure of most potential inhibitors for Ras [<xref ref-type="bibr" rid="B34-cells-08-00255">34</xref>]. New strategies are now focusing on the creation of an imbalance between Ras-specific GAP and GEF activities, as well as on the prevention of Ras from transducing its downstream proteins (<xref ref-type="fig" rid="cells-08-00255-f002">Figure 2</xref>) [<xref ref-type="bibr" rid="B69-cells-08-00255">69</xref>]. Despite these two setbacks, recent in silico techniques have identified new potential inhibitor binding sites in the Ras molecule, opening the possibility for the development of more effective Ras inhibitors [<xref ref-type="bibr" rid="B69-cells-08-00255">69</xref>].</p>
<p>Two of these regions in Ras, which are designated as sites 1 and 2 and are located between the switch 1 domain and the second α-helix (H2) structure, are the regions where the most important Ras GEF enzyme, son of sevenless homolog 1 (SOS1), binds and activates Ras [<xref ref-type="bibr" rid="B69-cells-08-00255">69</xref>,<xref ref-type="bibr" rid="B71-cells-08-00255">71</xref>]. Therefore, the occupancy of these sites with small inhibitory molecules could impede Ras guanine nucleotide exchange, preventing the activation of its downstream effectors [<xref ref-type="bibr" rid="B69-cells-08-00255">69</xref>,<xref ref-type="bibr" rid="B71-cells-08-00255">71</xref>]. Screening of molecular libraries has identified new inhibitory compounds with promising oncostatic effects on many carcinogenic cell lines [<xref ref-type="bibr" rid="B72-cells-08-00255">72</xref>]. For example, bisphenol A and its derivative 4,4’-biphenol can inhibit the proliferation of NIH3T3 cells [<xref ref-type="bibr" rid="B73-cells-08-00255">73</xref>] and some SCH-53870 derivatives can induce the death of NIH3T3 cell through the disruption of Ras and SOS binding [<xref ref-type="bibr" rid="B74-cells-08-00255">74</xref>]. The development of a synthetic α-helical structure which mimics SOS α helix and sequesters Ras-GDP molecules has been reported to be a possible new strategy for the treatment of Ras-overexpressing tumors [<xref ref-type="bibr" rid="B71-cells-08-00255">71</xref>]. Finally, some SAH-SOS1 inhibitors have been shown to be able to restrain the viability of Ras-overexpressing pancreatic, colon and lung cancer cells, demonstrating their potential use in cancer therapy [<xref ref-type="bibr" rid="B75-cells-08-00255">75</xref>].</p>
<p>Site 3, which is located between the switch 2 domain and the third α-helix of Ras, also corresponds to a GEF binding site [<xref ref-type="bibr" rid="B69-cells-08-00255">69</xref>]. SCH-54292, one of the first developed Ras inhibitors, binds this region in an inverse Mg<sup>2+</sup> concentration-dependent manner [<xref ref-type="bibr" rid="B76-cells-08-00255">76</xref>,<xref ref-type="bibr" rid="B77-cells-08-00255">77</xref>] and can restrain the growth of NIH3T3 cells by inducing apoptosis [<xref ref-type="bibr" rid="B78-cells-08-00255">78</xref>].</p>
<p>Sites 4 and 5 are located near the GTP-binding site and loop 7 of Ras and are the preferential joining site for divalent metal-cyclens (M<sup>2+</sup>-cyclens) [<xref ref-type="bibr" rid="B69-cells-08-00255">69</xref>,<xref ref-type="bibr" rid="B79-cells-08-00255">79</xref>]. M<sup>2+</sup>-cyclens are constituted by a divalent metallic ion (such as Zn<sup>2+</sup>, Co<sup>2+</sup> or Cu<sup>2+</sup>) attached to an organic cyclic structure [<xref ref-type="bibr" rid="B80-cells-08-00255">80</xref>,<xref ref-type="bibr" rid="B81-cells-08-00255">81</xref>]. These compounds can stabilize Ras-GTP in a pre-activated state, which is also known as state 1(T) [<xref ref-type="bibr" rid="B79-cells-08-00255">79</xref>]. The 1(T) intermediate displays lower affinity for its downstream effectors, as opposed to Ras-GTP in the state 2(T) conformation, which is able to effectively activate its effector molecules [<xref ref-type="bibr" rid="B79-cells-08-00255">79</xref>]. Therefore, the induction of Ras-GTP into state 1(T) by M<sup>2+</sup>-cyclens inhibits the Ras-related Raf activation pathway [<xref ref-type="bibr" rid="B79-cells-08-00255">79</xref>]. More potent organometallic compounds have been developed, such as Zn<sup>2+</sup>-bis (2-picolyl) amine (Zn<sup>2+</sup>-BPA), which blocks the activation of the downstream effectors of Ras through its specific binding to the loop L7 and switch 1 domains of this protein [<xref ref-type="bibr" rid="B79-cells-08-00255">79</xref>]. Zn<sup>2+</sup>-BPA can even inhibit the activation of some mutated Ras analogs without the previous requirement of having Ras bound to GTP [<xref ref-type="bibr" rid="B79-cells-08-00255">79</xref>]. All these mentioned properties allow the potential use of these compounds in the treatment of Ras-overexpressing tumors [<xref ref-type="bibr" rid="B79-cells-08-00255">79</xref>].</p>
<p>Another target with potential oncostatic effects in Ras-overexpressing tumors is the interaction of Ras and Raf, which is an essential step in the transduction of Ras signal [<xref ref-type="bibr" rid="B69-cells-08-00255">69</xref>]. For example, a derivative from enantiomeric iridium (III) that blocks the interaction of Ras with Raf, hinders the proliferation of different cancer cell lines and reduces tumor volume in mice kidney xenografts by inhibiting the Ras-Raf dependent activation of the MAPK pathway [<xref ref-type="bibr" rid="B82-cells-08-00255">82</xref>]. Similarly, R11.1.6, a poly-β sheet protein, can also block Ras and Raf interaction, as well as MAPK pathway activation in embryonic kidney cells, also making it a promising molecule in targeting Ras-overexpressing cancer [<xref ref-type="bibr" rid="B83-cells-08-00255">83</xref>]. Although NS1, a promising synthetic monobody has not been proven in preclinical models yet, it is a strong Ras inhibitory molecule that prevents Ras dimerization and Ras–Raf interaction due to its ability to specifically bind to the α4 and α5 helices of Ras [<xref ref-type="bibr" rid="B70-cells-08-00255">70</xref>]. Another method to inhibit the Ras–Raf interaction is the use of specific non-steroidal anti-inflammatory drugs (NSAIDs) [<xref ref-type="bibr" rid="B84-cells-08-00255">84</xref>,<xref ref-type="bibr" rid="B85-cells-08-00255">85</xref>]. Sulindac sulfide is an NSAID that can reduce tumorigenesis as well as colorectal and breast cancer proliferation in vitro [<xref ref-type="bibr" rid="B84-cells-08-00255">84</xref>,<xref ref-type="bibr" rid="B85-cells-08-00255">85</xref>]. Sulindac sulfide interacts with Ras in a non-covalent manner, which ultimately reduces its ability to transduce downstream cellular signaling [<xref ref-type="bibr" rid="B84-cells-08-00255">84</xref>,<xref ref-type="bibr" rid="B85-cells-08-00255">85</xref>]. Besides, other NSAIDs, such as aspirin or indomethacin, can also inhibit Ras and Raf protein interaction in vivo [<xref ref-type="bibr" rid="B86-cells-08-00255">86</xref>]. Finally, some members of MCP family, such as MCP1, MCP53 and MCP110, can also abolish Ras and Raf interaction by directly binding to the Ras effector domain and indirectly controlling Ras and Raf folding [<xref ref-type="bibr" rid="B87-cells-08-00255">87</xref>]. More in detail, MCP110 can inhibit the growth of colorectal tumor xenografts and sensitize colon cancer cells to different chemotherapeutical drugs such as paclitaxel, docetaxel, vincristine, and sorafenib, supporting its use in the treatment of Ras-overexpressing tumors [<xref ref-type="bibr" rid="B88-cells-08-00255">88</xref>].</p>
<p>Another approach to control the activity of Ras includes the activation of Ras-specific GAPs [<xref ref-type="bibr" rid="B89-cells-08-00255">89</xref>]. This process would increase the level of inactive Ras protein and consequently decrease downstream Ras signal transduction [<xref ref-type="bibr" rid="B89-cells-08-00255">89</xref>]. However, some Ras mutants have been reported to be insensitive to this inhibitory strategy because of the lack of certain amino acids inside their GAP-binding domain, impeding the action of these enzymes [<xref ref-type="bibr" rid="B69-cells-08-00255">69</xref>]. Screening of molecular libraries has identified several inducers that activate Ras GAPs [<xref ref-type="bibr" rid="B89-cells-08-00255">89</xref>]. For instance, repulsive guidance molecule A (RGMA), which is a synthetic protein that can extend neuronal axons, dissociates p120GAP from FAK, enhancing p120GAP activity and ultimately reducing cellular Ras-GTP content [<xref ref-type="bibr" rid="B90-cells-08-00255">90</xref>]. Semaphorin 4D (Sema4D), which is implied in the growth of neuronal system, can restrain integrin-mediated cancer cell invasion and migration through inducing Ras-specific GAP Plexin-B1 via direct protein–protein interaction [<xref ref-type="bibr" rid="B89-cells-08-00255">89</xref>,<xref ref-type="bibr" rid="B91-cells-08-00255">91</xref>].</p>
<p>Finally, another strategy for Ras inhibition is the disruption of its anchorage to the cytoplasmic membrane, which is an essential step during its activation [<xref ref-type="bibr" rid="B92-cells-08-00255">92</xref>]. For instance, salirasib (also known as trans-farnesylthiosalicylic acid) can act as the carboxyl-terminal farnesylcysteine carboxymethyl ester of Ras, exhibiting sufficient inhibitory properties to be used in Ras-overexpressing cancer treatment [<xref ref-type="bibr" rid="B92-cells-08-00255">92</xref>,<xref ref-type="bibr" rid="B93-cells-08-00255">93</xref>]. Indeed, this inhibitor reduces dose-dependently the growth of pancreatic and lung cancer xenografts [<xref ref-type="bibr" rid="B94-cells-08-00255">94</xref>,<xref ref-type="bibr" rid="B95-cells-08-00255">95</xref>], and restrains dose- and time-dependently the proliferation of pancreatic and liver cancer cells in vitro through arresting cell cycle progression and stimulating apoptotic cell death [<xref ref-type="bibr" rid="B96-cells-08-00255">96</xref>,<xref ref-type="bibr" rid="B97-cells-08-00255">97</xref>]. Besides, salisarib potentiates the restraining effects of Exo2 on prostate cancer proliferation, invasion and migration through inducing apoptotic cell death in both in vitro and in vivo models [<xref ref-type="bibr" rid="B44-cells-08-00255">44</xref>]. This inhibitor also stimulates gemcitabine-dependent reduction of tumor volume and weight, leading to increasing the survival rate of mice with pancreatic tumor xenografts [<xref ref-type="bibr" rid="B94-cells-08-00255">94</xref>]. Nevertheless, it has been claimed that the normally administered doses of salirasib are insufficient to inhibit the growth of lung carcinomas that carry mutations in Ras [<xref ref-type="bibr" rid="B98-cells-08-00255">98</xref>], failing in most in vivo assays due to the compensatory action of geranylgeranyl transferases [<xref ref-type="bibr" rid="B34-cells-08-00255">34</xref>,<xref ref-type="bibr" rid="B99-cells-08-00255">99</xref>]. In conclusion, more studies are required to determine its efficacy in cancer treatment.</p>
</sec>
<sec id="sec3dot2-cells-08-00255">
<title>3.2. Non-Chemical Mechanisms for Suppressing Ras Activity</title>
<p>Because of the difficulty finding effective Ras inhibitors, other more indirect anti-Ras strategies have recently arisen, such as the induction of certain Ras-related lethal genes or the restoration of the metabolism disturbances induced by this small GTPase [<xref ref-type="bibr" rid="B35-cells-08-00255">35</xref>].</p>
<p>One of these approaches consists in the detection of some specific genes that are essential for the growth of Ras-mutated cells, but not for Ras-wild type cells [<xref ref-type="bibr" rid="B35-cells-08-00255">35</xref>]. Therefore, the knockdown of these genes leads to reducing the effect of Ras mutations in tumor cell proliferation and ultimately emerging as an effective strategy in the prevention of tumorigenesis, as well as enhancing the efficacy of Ras inhibitors [<xref ref-type="bibr" rid="B35-cells-08-00255">35</xref>,<xref ref-type="bibr" rid="B100-cells-08-00255">100</xref>]. Currently, a great number of synthetic lethal interactors have been identified in Ras-mutated cells through siRNA screening [<xref ref-type="bibr" rid="B100-cells-08-00255">100</xref>,<xref ref-type="bibr" rid="B101-cells-08-00255">101</xref>,<xref ref-type="bibr" rid="B102-cells-08-00255">102</xref>]. Some of these interactors are implicated in Ras maturation, such as prenyl protein-specific endoprotease 2 (<italic>RCE1</italic>), and protein-S-isoprenylcysteine O-methyltransferase (<italic>ICMT</italic>); while others are Ras effectors, such as <italic>SHOC-2</italic>, phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 (<italic>PREX1</italic>) or <italic>RAF1</italic>; small GTPases, such as <italic>RAC1</italic>; or transcription factors, such as GATA-binding factor 1 (<italic>GATA1</italic>) [<xref ref-type="bibr" rid="B100-cells-08-00255">100</xref>,<xref ref-type="bibr" rid="B101-cells-08-00255">101</xref>,<xref ref-type="bibr" rid="B102-cells-08-00255">102</xref>]. However, the high differences existent among the different gene libraries makes this technique very inconsistent due to the high amount of false-negative results that occurs during the screening part [<xref ref-type="bibr" rid="B35-cells-08-00255">35</xref>]. Therefore, these protocols should be optimized to improve the sensitivity of this technique [<xref ref-type="bibr" rid="B35-cells-08-00255">35</xref>].</p>
<p>Another possible approach consists in the correction of the profound imbalances that the mutations in KRas generate in the metabolism of carcinogenic cells [<xref ref-type="bibr" rid="B35-cells-08-00255">35</xref>,<xref ref-type="bibr" rid="B103-cells-08-00255">103</xref>]. Indeed, KRas-mutated carcinogenic cells exhibit high levels of glucose uptake and glycolysis, fatty acid synthesis, glutaminolysis and nucleotide synthesis [<xref ref-type="bibr" rid="B103-cells-08-00255">103</xref>]. Due to the importance that these metabolic disturbances present in the maintenance of cancer promotion and progression, the methods that restore the metabolic rates to their basal levels could be an effective anti-cancer strategy [<xref ref-type="bibr" rid="B103-cells-08-00255">103</xref>]. In fact, tumorigenesis rate and pancreatic inflammation and fibrosis are clearly aggravated in mice carrying KRas tumors and are fed with high-fat diet [<xref ref-type="bibr" rid="B104-cells-08-00255">104</xref>]. The induction of autophagic response in KRas-mutated cells stimulates tumor aggressiveness and proliferation by accelerating glycolytic capability [<xref ref-type="bibr" rid="B105-cells-08-00255">105</xref>,<xref ref-type="bibr" rid="B106-cells-08-00255">106</xref>]. Indeed, autophagy inhibition in KRas-overexpressing tumors could decrease tumor promotion and progression [<xref ref-type="bibr" rid="B105-cells-08-00255">105</xref>,<xref ref-type="bibr" rid="B106-cells-08-00255">106</xref>].</p>
</sec>
</sec>
<sec id="sec4-cells-08-00255">
<title>4. Rac and Its Inhibitors in Cancer Therapy</title>
<p>Rac presents key functions in cancer promotion and progression since the aberrant expression of this small GTPase disrupts adherens cellular junctions, allowing cancer cells to undergo EMT and cell migration [<xref ref-type="bibr" rid="B21-cells-08-00255">21</xref>,<xref ref-type="bibr" rid="B107-cells-08-00255">107</xref>]. This alteration on Rac expression also enhances cellular proliferation by facilitating cell cycle progression from G1 to S phase and stimulating mitosis and cytokinesis [<xref ref-type="bibr" rid="B21-cells-08-00255">21</xref>,<xref ref-type="bibr" rid="B107-cells-08-00255">107</xref>]. Rac involvement in the reverse process of mesenchymal to epithelial transition (MET) facilitates the formation of secondary tumors [<xref ref-type="bibr" rid="B107-cells-08-00255">107</xref>]. These finding suggest that inhibition of Rac could be useful for cancer treatment [<xref ref-type="bibr" rid="B107-cells-08-00255">107</xref>]. The inhibitors that are currently available to block this protein, as well as their mechanism of action, are listed in <xref ref-type="table" rid="cells-08-00255-t003">Table 3</xref></p>
<p>NSC23766 was one of the first developed Rac1 inhibitors with capability to discern from other Rho family GTPases, such as Cdc42 or RhoA [<xref ref-type="bibr" rid="B108-cells-08-00255">108</xref>]. This synthetic compound binds to a zone located between the switch I, switch II and β1/β2/β3 regions of this protein [<xref ref-type="bibr" rid="B108-cells-08-00255">108</xref>], impeding its activation by occupying the location where two RacGEF enzymes, Trio and T-lymphoma invasion and metastasis-inducing protein 1 (Tiam1) join together with this GTPase [<xref ref-type="bibr" rid="B108-cells-08-00255">108</xref>,<xref ref-type="bibr" rid="B109-cells-08-00255">109</xref>]. Due to the restrictive effects that present in Rac activation, NSC23766 has been proven to impede cell proliferation in both carcinogenic and non-carcinogenic cells [<xref ref-type="bibr" rid="B109-cells-08-00255">109</xref>]. For instance, this inhibitor can restrain prostate cancer proliferation and mobility, sensitize prostate cancer cells to ionizing radiotherapy, and inhibit non-small cell lung cancer (NSCLC) proliferation and invasion both in vivo and in vitro [<xref ref-type="bibr" rid="B109-cells-08-00255">109</xref>,<xref ref-type="bibr" rid="B110-cells-08-00255">110</xref>,<xref ref-type="bibr" rid="B111-cells-08-00255">111</xref>]. Inversely, this inhibitor was unable to prevent high-metastatic breast cancer cells migration, thus some new NSC23766 derivatives should be developed to improve its efficiency to restrain these types of cancers, as well as to reduce the administered doses [<xref ref-type="bibr" rid="B112-cells-08-00255">112</xref>].</p>
<p>One derivative of NSC23766, EHop-016, inhibits Rac activation through disrupting its direct binding to Vav2 (a Rho-specific GEF) [<xref ref-type="bibr" rid="B113-cells-08-00255">113</xref>], giving it a 100-fold lower IC<sub>50</sub> against this GTPase than NSC23766, which encourages its use instead its derivative in cancer therapy [<xref ref-type="bibr" rid="B113-cells-08-00255">113</xref>,<xref ref-type="bibr" rid="B114-cells-08-00255">114</xref>,<xref ref-type="bibr" rid="B115-cells-08-00255">115</xref>,<xref ref-type="bibr" rid="B116-cells-08-00255">116</xref>]. In fact, EHop-016 can inhibit the proliferation of breast, myxofibrosarcoma and leukemic cancer cells in vitro, as well as impair their invasive capabilities [<xref ref-type="bibr" rid="B113-cells-08-00255">113</xref>,<xref ref-type="bibr" rid="B115-cells-08-00255">115</xref>,<xref ref-type="bibr" rid="B116-cells-08-00255">116</xref>]. It can also reduce the proliferation, angiogenesis and invasion of breast xenografts, diminishing the generation of secondary tumors in lung, liver, spleen and kidneys [<xref ref-type="bibr" rid="B114-cells-08-00255">114</xref>]. Besides, it reduces the growth of myxofibrosarcoma xenografts by restraining Rac-derived Akt/mTORC1 and mTORC2 activation [<xref ref-type="bibr" rid="B116-cells-08-00255">116</xref>]. Alternatively, this inhibitor has also been proven useful in the treatment of some non-carcinogenic disorders since it prevents glucose-induced insulin secretion and actin remodeling in pancreatic β cells [<xref ref-type="bibr" rid="B117-cells-08-00255">117</xref>].</p>
<p>EHT 1864 impedes the formation of the Rac-Tiam1 complex, keeping this GTPase in an inactive state [<xref ref-type="bibr" rid="B118-cells-08-00255">118</xref>]. This inhibitor is unable to inhibit other Rac-related Rho-family GTPases, demonstrating high specificity [<xref ref-type="bibr" rid="B118-cells-08-00255">118</xref>,<xref ref-type="bibr" rid="B119-cells-08-00255">119</xref>]. EHT 1864 exhibits promising potential properties to be used during cancer treatment [<xref ref-type="bibr" rid="B119-cells-08-00255">119</xref>,<xref ref-type="bibr" rid="B120-cells-08-00255">120</xref>]. For example, it can repress estrogen-induced breast cancer cell proliferation through modulating the Rac-dependent estrogen receptor-alpha (ERα) expression, as well as hampers NIH3T3 Rac-dependent Ras-induced tumorigenesis [<xref ref-type="bibr" rid="B119-cells-08-00255">119</xref>,<xref ref-type="bibr" rid="B120-cells-08-00255">120</xref>]. Besides, it prevents breast cancer invasion and proliferation, as well as inducing apoptosis through inhibiting STAT3 in patient-derived samples [<xref ref-type="bibr" rid="B121-cells-08-00255">121</xref>]. Finally, it can also sensitize breast carcinogenic cells to tamoxifen, since Rac1 overexpression seems to be a hallmark in the acquisition of cell resistance to this drug [<xref ref-type="bibr" rid="B120-cells-08-00255">120</xref>].</p>
<p>YM1B, which is a monoclonal antibody against CCN1, can halt breast cancer migration and invasion through inhibiting Rac induction and actin reorganization [<xref ref-type="bibr" rid="B122-cells-08-00255">122</xref>]. Besides, the generation of aptamers that inhibit Tiam1 activity, by impeding the binding of Rac1 to this molecule and decreasing its activation, is a new strategy to inactivation of this GTPase in the treatment of the tumors that overexpress Rac1 [<xref ref-type="bibr" rid="B123-cells-08-00255">123</xref>]. Conversely, binder of Arl Two (BART) abrogated carcinogenic cell mobility due to its capability to restrain the activation of this small GTPase [<xref ref-type="bibr" rid="B124-cells-08-00255">124</xref>]. Finally, core macrolactam and core macroketone, which are two migrastatin analogs, can also abolish breast cancer migration through inhibiting Rac activation [<xref ref-type="bibr" rid="B125-cells-08-00255">125</xref>].</p>
<p>Nevertheless, the constant use of Rac inhibitors in cancer treatment could generate some off-target effects in platelets because of the indirect inhibition of p21-activated kinase 1/2 (PAK1/2) [<xref ref-type="bibr" rid="B126-cells-08-00255">126</xref>], thus the administration of those Rac inhibitors should be controlled and interrupted when these undesired effects arise.</p>
</sec>
<sec id="sec5-cells-08-00255">
<title>5. Cdc42 and Its Inhibitors in Cancer Therapy</title>
<p>Cdc42, which belongs to the Rho family [<xref ref-type="bibr" rid="B127-cells-08-00255">127</xref>], takes part in the initiation of most human cancers [<xref ref-type="bibr" rid="B21-cells-08-00255">21</xref>,<xref ref-type="bibr" rid="B128-cells-08-00255">128</xref>] since it induces the proliferation of Ras-transformed carcinogenic cells by inducing cell cycle progression [<xref ref-type="bibr" rid="B129-cells-08-00255">129</xref>], as well as stimulates tumorigenesis through impeding the degradation of EGFR by ubiquitin-proteasome system [<xref ref-type="bibr" rid="B128-cells-08-00255">128</xref>,<xref ref-type="bibr" rid="B130-cells-08-00255">130</xref>]. In addition, Cdc42 also enhances metastasis, invasion and EMT [<xref ref-type="bibr" rid="B127-cells-08-00255">127</xref>,<xref ref-type="bibr" rid="B131-cells-08-00255">131</xref>]. These properties back up the development of Cdc42 inhibitors as a great strategy to be used in the treatment of several malignant diseases. The inhibitors that are currently available to block this protein, as well as their mechanism of action, are listed in <xref ref-type="table" rid="cells-08-00255-t003">Table 3</xref>.</p>
<p>Secramine A, a synthetic derivate of galantamine, can disturb the recruitment of prenylated Cdc42 to the Golgi apparatus membrane by blocking Rho guanine dissociation inhibitor 1 (RhoGDI1), which modulates its attachment to this membrane [<xref ref-type="bibr" rid="B132-cells-08-00255">132</xref>,<xref ref-type="bibr" rid="B133-cells-08-00255">133</xref>]. Indeed, the inhibition of Cdc42 activity by this molecule generates a significant reduction in the proliferation of anaplastic large cell lymphoma cells through inducing apoptotic cell death [<xref ref-type="bibr" rid="B134-cells-08-00255">134</xref>]. Curiously, the lack of anaplastic lymphoma kinase (ALK) in these cells hinders the capability of secramine A to induce this phenotype, thus its utilization should be restrained to the cells that express this protein [<xref ref-type="bibr" rid="B134-cells-08-00255">134</xref>]. Otherwise, this inhibitor has also been shown to restrain other non-carcinogenic pathophysiological processes [<xref ref-type="bibr" rid="B135-cells-08-00255">135</xref>,<xref ref-type="bibr" rid="B136-cells-08-00255">136</xref>,<xref ref-type="bibr" rid="B137-cells-08-00255">137</xref>]. For example, secramine A alters fertilization process by reducing progesterone-induced and spontaneous acrosome reaction in mammalian sperm [<xref ref-type="bibr" rid="B135-cells-08-00255">135</xref>], reduces the propagation of human immunodeficiency virus (HIV) in cluster of differentiation 4 (CD4)<sup>+</sup> T lymphocytes [<xref ref-type="bibr" rid="B136-cells-08-00255">136</xref>] and disturbs the release of collagen I from vascular smooth muscle cells to the cell matrix [<xref ref-type="bibr" rid="B137-cells-08-00255">137</xref>]. Nevertheless, some harmful off-target effects have been reported during the administration of this compound, limiting its use in carcinogenic and non-carcinogenic diseases [<xref ref-type="bibr" rid="B138-cells-08-00255">138</xref>].</p>
<p>Another potential inhibitor of Cdc42 with therapeutic applications in cancer is ZCL278, a 4-bromine-2-chlorophenol derivative that disrupts the joining between Cdc42 and intersectin (ITSN), which is a Cdc42-specific GEF enzyme, leading to inhibiting the activation of this small GTPase [<xref ref-type="bibr" rid="B139-cells-08-00255">139</xref>,<xref ref-type="bibr" rid="B140-cells-08-00255">140</xref>]. ZCL278 presents promising properties for being used in cancer therapy, such as a high membrane permeability and low toxicity for non-carcinogenic cells [<xref ref-type="bibr" rid="B137-cells-08-00255">137</xref>]. For example, ZCL278 can restrain the migratory and invasive characteristics of the prostate cancer cell line PC3 in vitro [<xref ref-type="bibr" rid="B139-cells-08-00255">139</xref>]. In addition, it can also prevent the toxicity of sodium arsenite (NaAsO<sub>2</sub>) on astrocytes and cerebellar granule neurons, encouraging its use to alleviate arsenic poisoning on the nervous system [<xref ref-type="bibr" rid="B141-cells-08-00255">141</xref>,<xref ref-type="bibr" rid="B142-cells-08-00255">142</xref>].</p>
<p>ML141 (also known as CID2950007 or CID2995007) and its analog CID44216842 are selective Cdc42 inhibitors that can deactivate this small GTPase in a non-competitive and allosteric manner by locking this protein in an inactive conformation [<xref ref-type="bibr" rid="B34-cells-08-00255">34</xref>,<xref ref-type="bibr" rid="B143-cells-08-00255">143</xref>]. Although these molecules are unable to induce any anti-proliferative effects in ovarian cancer cells, they can restrain dose-dependently their mobility, which indicates their possible use as a therapeutic adjuvants to reduce the arising of secondary tumors [<xref ref-type="bibr" rid="B138-cells-08-00255">138</xref>].</p>
<p>Additionally, some double Rac/Cdc42 inhibitors have been developed due to the similar roles these two small GTPases perform in cancer promotion and progression [<xref ref-type="bibr" rid="B144-cells-08-00255">144</xref>]. For instance, MBQ-167, which seems to inhibit the activation of Rac and Cdc42 by occupying their effector domain, prevents breast cancer cell migration, reduces cell viability, and impedes EMT progression by disrupting cell polarity without affecting non-carcinogenic cells growth (<xref ref-type="table" rid="cells-08-00255-t003">Table 3</xref>) [<xref ref-type="bibr" rid="B144-cells-08-00255">144</xref>]. N*2*,N*4*-Bis-(2-methyl-1H-indol-5-yl)-pyrimidine-2,4-diamine (AZA1), which is a structural derivative of NSC23766, can repress tumor growth and abolish cell migration in prostate xenografts (<xref ref-type="table" rid="cells-08-00255-t003">Table 3</xref>) [<xref ref-type="bibr" rid="B145-cells-08-00255">145</xref>]. Otherwise, R-ketorolac, which is an enantiomer of the analgesic S-ketorolac, can diminish cell adhesion to extracellular matrix and invasion in ovarian cancer cells, validating its possible use in cancer therapy [<xref ref-type="bibr" rid="B146-cells-08-00255">146</xref>].</p>
</sec>
<sec id="sec6-cells-08-00255">
<title>6. Targeting other Small GTPases in Cancer Therapy</title>
<p>RhoA is an oncogene that induces tumor progression through enhancing carcinogenic cell proliferation, angiogenesis, invasion and metastasis [<xref ref-type="bibr" rid="B21-cells-08-00255">21</xref>,<xref ref-type="bibr" rid="B147-cells-08-00255">147</xref>], suggesting the development of RhoA inhibitors could be a great strategy to restrain cancer promotion and progression [<xref ref-type="bibr" rid="B36-cells-08-00255">36</xref>]. However, the generation of these inhibitors present several challenges due to the absence of stable cavities in the surface of RhoA, apart from the nucleotide-binding pocket, as well as its ability to capture guanine nucleotides at sub-nanomolar range [<xref ref-type="bibr" rid="B36-cells-08-00255">36</xref>]. Therefore, new strategies should be carried out to inhibit RhoA in cancer cells (<xref ref-type="fig" rid="cells-08-00255-f002">Figure 2</xref>) [<xref ref-type="bibr" rid="B36-cells-08-00255">36</xref>]. The inhibitors that are currently available to block this oncogene, as well as their mechanism of action, are listed in <xref ref-type="table" rid="cells-08-00255-t003">Table 3</xref>.</p>
<p>Despite these difficulties, some promising RhoA inhibitors have already been developed to be used in cancer treatment [<xref ref-type="bibr" rid="B36-cells-08-00255">36</xref>]. For instance, Rhosin, which disturbs RhoA activation by binding to its W58 and impeding the docking of GEF enzymes [<xref ref-type="bibr" rid="B148-cells-08-00255">148</xref>], can inhibit breast cancer cell proliferation, migration and invasion in vitro and restrain the formation of spheroid bodies in gastric cancer cells [<xref ref-type="bibr" rid="B148-cells-08-00255">148</xref>,<xref ref-type="bibr" rid="B149-cells-08-00255">149</xref>]. On the other hand, Y16, which also prevents the binding between RhoA and its GEF enzymes by binding between the DH and PH domains of Leukemia-associated RhoGEF (LARG), suppresses breast cancer proliferation, migration and invasion, as well as modifies the distribution of the actin cytoskeleton [<xref ref-type="bibr" rid="B150-cells-08-00255">150</xref>]. Both inhibitors synergize to more efficiently hinder the interaction between RhoA and LARG, intensifying the reduction of breast cancer proliferation and invasion and allowing their use in the treatment of RhoA-overexpressing tumors [<xref ref-type="bibr" rid="B150-cells-08-00255">150</xref>].</p>
<p>CHS-111 is a benzyl indazole derivative that prevents both the joining of RhoA to membranes and its activation by its GEF enzyme Vav by preventing its interaction with phospholipase D1 (PLD1) [<xref ref-type="bibr" rid="B151-cells-08-00255">151</xref>]. Although there is no CHS-111 preclinical study, it might be useful in the treatment of RhoA overexpressing cancers.</p>
<p>Rab family constituents are also involved in the pathogenesis of some cancer types, such as hepatocellular carcinoma, cholangiohepatoma, gastric cancer, lung cancer, renal cancer, breast cancer, tongue and oral squamous cell carcinoma, as well as ovarian cancer [<xref ref-type="bibr" rid="B26-cells-08-00255">26</xref>,<xref ref-type="bibr" rid="B152-cells-08-00255">152</xref>,<xref ref-type="bibr" rid="B153-cells-08-00255">153</xref>,<xref ref-type="bibr" rid="B154-cells-08-00255">154</xref>,<xref ref-type="bibr" rid="B155-cells-08-00255">155</xref>,<xref ref-type="bibr" rid="B156-cells-08-00255">156</xref>,<xref ref-type="bibr" rid="B157-cells-08-00255">157</xref>], because they can promote cancer progression and aggressiveness by inducing invasion, metastasis, proliferation and cell cycle progression [<xref ref-type="bibr" rid="B26-cells-08-00255">26</xref>,<xref ref-type="bibr" rid="B157-cells-08-00255">157</xref>,<xref ref-type="bibr" rid="B158-cells-08-00255">158</xref>]. Rab protein overexpression also increases the resistance of carcinogenic cells to chemotherapy [<xref ref-type="bibr" rid="B159-cells-08-00255">159</xref>]. Despite the role of this family of small GTPases in cancer, few effective Rab inhibitors are available for cancer treatment [<xref ref-type="bibr" rid="B160-cells-08-00255">160</xref>]. Among them, Rab geranylgeranyltransferase (RabGGTase) inhibitors are the most promising molecules to be used in Rab-overexpressing tumors [<xref ref-type="bibr" rid="B160-cells-08-00255">160</xref>]. These inhibitors prevent the addition of geranyl groups in the C-termini of Rabs, which are necessary for ensuring their attachment to cellular membranes [<xref ref-type="bibr" rid="B160-cells-08-00255">160</xref>]. RabGGTases present promising effects in cancer therapy because they can effectively restrain human myeloma and mesothelioma cell proliferation in vitro by inducing apoptosis and cell cycle arrest, as well as reduce prostate and breast cancer adhesion and metastasis by suppressing the proteolytic activity of matrix metalloproteinases (MMPs) [<xref ref-type="bibr" rid="B161-cells-08-00255">161</xref>,<xref ref-type="bibr" rid="B162-cells-08-00255">162</xref>,<xref ref-type="bibr" rid="B163-cells-08-00255">163</xref>,<xref ref-type="bibr" rid="B164-cells-08-00255">164</xref>]. Therefore, we can conclude that RabGGTases show promising in vivo effects, preventing the growth of different skeletal tumors [<xref ref-type="bibr" rid="B165-cells-08-00255">165</xref>].</p>
</sec>
<sec id="sec7-cells-08-00255" sec-type="conclusions">
<title>7. Conclusions</title>
<p>Small GTPases are upregulated in a broad spectrum of human cancers since they have the potential to promote cell proliferation and mobility as well as to stimulate their invasive and metastatic characteristics. However, no inhibitors are currently available for its normal use in clinical therapy. Indeed, small GTPases are difficult to target because they present few stable cavities for inhibitors to bind on their surface and they can capture guanine nucleotides at sub-nanomolar range. To achieve the inhibition of these molecules, some new strategies have recently arisen, such as the inhibition of the binding between GTPase and GEF, the enhancement of GAP activity, the hindering of nucleotide attachment, the blocking of their binding to cellular membranes, or the inhibition of the activity of their downstream effectors. However, most of the new drugs that hamper these strategies have only been proven successful in in vitro studies, while demonstrating fewer promising abilities at the in vivo model and clinical trial stages. These discrepancies normally occur because of the enhancement of some compensatory mechanisms that mask the effect of the inhibitor. Therefore, more in vivo studies should be performed to further evaluate the capability of these inhibitors to impede cancer progression and reduce cancer chemoresistance.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank Austin Shull and Cooley Marion for their input. We apologize to numerous colleagues whose work could not be cited in this article due to space limitation.</p>
</ack>
<notes>
<title>Funding</title>
<p>This research was supported by NIH grant R03DE028387 (to YT). NPD conducted his study under supervision of YT at Augusta University supported by the Spanish Ministry of Education, Culture and Sports (“Becas FPU 2013”, reference FPU13/04173 and “Ayudas a la movilidad para estancias breves y traslados temporales 2016”, reference EST 16/00783).</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ALK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Anaplastic lymphoma kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ARL</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Arf-like proteins</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ARNO</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Arf nucleotide-binding site opener</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AZA1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">N*2*,N*4*-Bis-(2-methyl-1H-indol-5-yl)-pyrimidine-2,4-diamine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BART</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Binder of Arl Two</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BFA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Brefeldin A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CD4</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cluster of differentiation 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Cdc42</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cell division control protein 42 homolog</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CERT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ceramide transfer protein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">EGFR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Epithelial growth factor receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">EMT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Epithelial to mesenchymal transition</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ER</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Endoplasmic reticulum</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ERK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Extracellular signal-regulated kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ERα</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Estrogen receptor-alpha</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Exo84</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Exocyst complex component 84</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FAK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Focal adhesion kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FAPP1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phosphatidylinositol-four-phosphate adapter protein 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GAP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">GTPase-activating proteins</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GATA1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">GATA-binding factor 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GEF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Guanine-nucleotide exchange factors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GRE</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Rad and Gem-related proteins</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">H2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Second α-helix of Ras</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HIV</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Human immunodeficiency virus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HNSCC</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Head and neck squamous cell carcinoma</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">IMCT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Protein-S-isoprenylcysteine O-methyltransferase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ITSN</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Intersectin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LARG</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Leukemia-associated RhoGEF</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">M<sup>2+</sup>-cyclens</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Divalent metal-cyclens</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">M6PR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Mannose-6-phosphate receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MAPK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Mitogen-activated protein kinases</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MET</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Mesenchymal to epithelial transition</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Miro</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Mitochondrial Rho GTPase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MMP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Matrix metalloproteinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">mTORC1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">mechanistic target of rapamycin complex 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NF-κB</td>
<td align="left" colspan="1" rowspan="1" valign="middle">nuclear factor-κB</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NSAID</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Non-small cell lung cancer</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">p70S6K</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ribosomal protein S6 kinase beta-1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PAK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">p21-activated kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PI3K</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phosphatidylinositol 3-kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PLCε</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phospholipase C epsilon</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PLD1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phospholipase D1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PREX1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Rab</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-related in brain</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RabGGTase</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Rab geranylgeranyltransferase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Rac</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-related C3 botulinum toxin substrate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Rac1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-related C3 botulinum toxin substrate 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Rad</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-related associated with diabetes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Ral</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-like proteins</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Ran</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-related nuclear protein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Rap</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-proximal proteins</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RCE1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Prenyl protein-specific endoprotease 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RGMA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Repulsive guidance molecule A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Rheb</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras homolog enriched in brain</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Rho</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-homolog</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RhoA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Rho-related proteins</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RhoBTB3</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Rho-related BTB domain-containing protein 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RhoGDI1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Rho guanine dissociation inhibitor 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Rit</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-like in all tissues proteins</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Rnd</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Rho-related GTP-binding protein Rho6 precursor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RRAS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ras-related proteins</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SecinH3</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sec7 inhibitor H3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Sema4D</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Semaphorin 4D</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SNARE</td>
<td align="left" colspan="1" rowspan="1" valign="middle">NSF-attachment protein receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SOS1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Son of sevenless homolog 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">STAT3</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Signal transducer and activator of transcription 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TCL</td>
<td align="left" colspan="1" rowspan="1" valign="middle">TC10 and T-cell leukemia/lymphoma protein 1A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Tiam1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">T-lymphoma invasion and metastasis-inducing protein 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">VEGFR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">VEGF receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">VEGF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Vascular endothelial growth factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Zn<sup>2+</sup>-BPA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Zn<sup>2+</sup>-bis (2-picolyl) amine</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-cells-08-00255">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Citi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Spadaro</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Stutz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pulimeno</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Regulation of small GTPases at epithelial cell-cell junctions</article-title>
<source/>Mol. Membr. Biol.
          <year>2011</year>
<volume>28</volume>
<fpage>427</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="doi">10.3109/09687688.2011.603101</pub-id>
<pub-id pub-id-type="pmid">21781017</pub-id>
</element-citation>
</ref>
<ref id="B2-cells-08-00255">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Nassar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A mechanism of catalyzed GTP hydrolysis by Ras protein through magnesium ion</article-title>
<source/>Chem. Phys. Lett.
          <year>2011</year>
<volume>516</volume>
<fpage>233</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="doi">10.1016/j.cplett.2011.09.071</pub-id>
</element-citation>
</ref>
<ref id="B3-cells-08-00255">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>G.X.</given-names>
</name>
<name>
<surname>Andres</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Ras family small GTPase-mediated neuroprotective signaling in stroke</article-title>
<source/>Cent. Nerv. Syst. Agents Med. Chem.
          <year>2011</year>
<volume>11</volume>
<fpage>114</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.2174/187152411796011349</pub-id>
<pub-id pub-id-type="pmid">21521171</pub-id>
</element-citation>
</ref>
<ref id="B4-cells-08-00255">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.H.</given-names>
</name>
</person-group>
<article-title>Ras family of small GTPases in immunity and inflammation</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2012</year>
<volume>12</volume>
<fpage>458</fpage>
<lpage>463</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2012.02.003</pub-id>
<pub-id pub-id-type="pmid">22401931</pub-id>
</element-citation>
</ref>
<ref id="B5-cells-08-00255">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wennerberg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rossman</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Der</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>The Ras superfamily at a glance</article-title>
<source/>J. Cell Sci.
          <year>2005</year>
<volume>118</volume>
<fpage>843</fpage>
<lpage>846</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.01660</pub-id>
<pub-id pub-id-type="pmid">15731001</pub-id>
</element-citation>
</ref>
<ref id="B6-cells-08-00255">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heider</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hauke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pyka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Insights into the classification of small GTPases</article-title>
<source/>Adv. Appl. Bioinforma. Chem.
          <year>2010</year>
<volume>3</volume>
<fpage>15</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.2147/AABC.S8891</pub-id>
</element-citation>
</ref>
<ref id="B7-cells-08-00255">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colicelli</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Human RAS superfamily proteins and related GTPases</article-title>
<source/>Sci. STKE
          <year>2004</year>
<volume>2004</volume>
<fpage>RE13</fpage>
<pub-id pub-id-type="doi">10.1126/stke.2502004re13</pub-id>
<pub-id pub-id-type="pmid">15367757</pub-id>
</element-citation>
</ref>
<ref id="B8-cells-08-00255">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donaldson</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>C.L.</given-names>
</name>
</person-group>
<article-title>Arf family G proteins and their regulators: Roles in membrane transport, development and disease</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2011</year>
<volume>12</volume>
<fpage>362</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3117</pub-id>
<pub-id pub-id-type="pmid">21587297</pub-id>
</element-citation>
</ref>
<ref id="B9-cells-08-00255">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Snapshots of ARF1: Implications for mechanisms of activation and inactivation</article-title>
<source/>Cell
          <year>1999</year>
<volume>97</volume>
<fpage>149</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)80723-0</pub-id>
<pub-id pub-id-type="pmid">10219234</pub-id>
</element-citation>
</ref>
<ref id="B10-cells-08-00255">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casalou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Faustino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barral</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>Arf proteins in cancer cell migration</article-title>
<source/>Small GTPases
          <year>2016</year>
<volume>7</volume>
<fpage>270</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1080/21541248.2016.1228792</pub-id>
<pub-id pub-id-type="pmid">27589148</pub-id>
</element-citation>
</ref>
<ref id="B11-cells-08-00255">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kannangai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vivekanandan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Martinez-Murillo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Choti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Torbenson</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways</article-title>
<source/>Hum. Pathol.
          <year>2007</year>
<volume>38</volume>
<fpage>639</fpage>
<lpage>644</lpage>
<pub-id pub-id-type="doi">10.1016/j.humpath.2006.07.019</pub-id>
<pub-id pub-id-type="pmid">17367606</pub-id>
</element-citation>
</ref>
<ref id="B12-cells-08-00255">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>39834</fpage>
<lpage>39845</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.9405</pub-id>
<pub-id pub-id-type="pmid">27213581</pub-id>
</element-citation>
</ref>
<ref id="B13-cells-08-00255">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schlienger</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Claing</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>ARF1 regulates adhesion of MDA-MB-231 invasive breast cancer cells through formation of focal adhesions</article-title>
<source/>Cell. Signal.
          <year>2015</year>
<volume>27</volume>
<fpage>403</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2014.11.032</pub-id>
<pub-id pub-id-type="pmid">25530216</pub-id>
</element-citation>
</ref>
<ref id="B14-cells-08-00255">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Roles of Arf6 in cancer cell invasion, metastasis and proliferation</article-title>
<source/>Life Sci.
          <year>2017</year>
<volume>182</volume>
<fpage>80</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2017.06.008</pub-id>
<pub-id pub-id-type="pmid">28625359</pub-id>
</element-citation>
</ref>
<ref id="B15-cells-08-00255">
<label>15.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Goitre</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Trapani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Trabalzini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Retta</surname>
<given-names>S.F.</given-names>
</name>
</person-group>
<article-title>The Ras superfamily of small GTPases: The unlocked secrets</article-title>
<source/>Ras Signaling: Methods and Protocols
          <person-group person-group-type="editor">
<name>
<surname>Trabalzini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Retta</surname>
<given-names>S.F.</given-names>
</name>
</person-group>
<publisher-name>Springer</publisher-name>
<publisher-loc>Berlin, Germany</publisher-loc>
<year>2014</year>
<volume>Volume 1120</volume>
<fpage>1</fpage>
<lpage>18</lpage>
<isbn>9781627037914</isbn>
</element-citation>
</ref>
<ref id="B16-cells-08-00255">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shirakawa</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Ral GTPases: Crucial mediators of exocytosis and tumourigenesis</article-title>
<source/>J. Biochem.
          <year>2015</year>
<volume>157</volume>
<fpage>285</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1093/jb/mvv029</pub-id>
<pub-id pub-id-type="pmid">25796063</pub-id>
</element-citation>
</ref>
<ref id="B17-cells-08-00255">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rap2B promotes proliferation, migration, and invasion of human breast cancer through calcium-related ERK1/2 signaling pathway</article-title>
<source/>Sci. Rep.
          <year>2015</year>
<volume>5</volume>
<fpage>12363</fpage>
<pub-id pub-id-type="doi">10.1038/srep12363</pub-id>
<pub-id pub-id-type="pmid">26201295</pub-id>
</element-citation>
</ref>
<ref id="B18-cells-08-00255">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gloerich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bos</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Regulating Rap small G-proteins in time and space</article-title>
<source/>Trends Cell Biol.
          <year>2011</year>
<volume>21</volume>
<fpage>615</fpage>
<lpage>623</lpage>
<pub-id pub-id-type="doi">10.1016/j.tcb.2011.07.001</pub-id>
<pub-id pub-id-type="pmid">21820312</pub-id>
</element-citation>
</ref>
<ref id="B19-cells-08-00255">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armijo</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fuentes-Villalobos</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Palma</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Pincheira</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>A.F.</given-names>
</name>
</person-group>
<article-title>Rheb signaling and tumorigenesis: mTORC1 and new horizons</article-title>
<source/>Int. J. Cancer
          <year>2016</year>
<volume>138</volume>
<fpage>1815</fpage>
<lpage>1823</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.29707</pub-id>
<pub-id pub-id-type="pmid">26234902</pub-id>
</element-citation>
</ref>
<ref id="B20-cells-08-00255">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>G.X.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Andres</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Rit subfamily small GTPases: Regulators in neuronal differentiation and survival</article-title>
<source/>Cell Signal.
          <year>2013</year>
<volume>25</volume>
<fpage>2060</fpage>
<lpage>2068</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2013.06.002</pub-id>
<pub-id pub-id-type="pmid">23770287</pub-id>
</element-citation>
</ref>
<ref id="B21-cells-08-00255">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karlsson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Brakebusch</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Rho GTPase function in tumorigenesis</article-title>
<source/>Biochim. Biophys. Acta
          <year>2009</year>
<volume>1796</volume>
<fpage>91</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbcan.2009.03.003</pub-id>
<pub-id pub-id-type="pmid">19327386</pub-id>
</element-citation>
</ref>
<ref id="B22-cells-08-00255">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors</article-title>
<source/>Small GTPases
          <year>2018</year>
<volume>9</volume>
<fpage>203</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1080/21541248.2016.1218407</pub-id>
<pub-id pub-id-type="pmid">27548350</pub-id>
</element-citation>
</ref>
<ref id="B23-cells-08-00255">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadok</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Rho GTPases: Masters of cell migration</article-title>
<source/>Small GTPases
          <year>2014</year>
<volume>5</volume>
<fpage>e29710</fpage>
<pub-id pub-id-type="doi">10.4161/sgtp.29710</pub-id>
<pub-id pub-id-type="pmid">24978113</pub-id>
</element-citation>
</ref>
<ref id="B24-cells-08-00255">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subramani</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Alahari</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>Integrin-mediated function of Rab GTPases in cancer progression</article-title>
<source/>Mol. Cancer
          <year>2010</year>
<volume>9</volume>
<fpage>312</fpage>
<pub-id pub-id-type="doi">10.1186/1476-4598-9-312</pub-id>
<pub-id pub-id-type="pmid">21143914</pub-id>
</element-citation>
</ref>
<ref id="B25-cells-08-00255">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenmark</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Rab GTPases as coordinators of vesicle traffic</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2009</year>
<volume>10</volume>
<fpage>513</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="doi">10.1038/nrm2728</pub-id>
<pub-id pub-id-type="pmid">19603039</pub-id>
</element-citation>
</ref>
<ref id="B26-cells-08-00255">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Rab25 GTPase: Functional roles in cancer</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>64591</fpage>
<lpage>64599</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.19571</pub-id>
<pub-id pub-id-type="pmid">28969096</pub-id>
</element-citation>
</ref>
<ref id="B27-cells-08-00255">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Molecular mechanism of the nuclear protein import cycle</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2007</year>
<volume>8</volume>
<fpage>195</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="doi">10.1038/nrm2114</pub-id>
<pub-id pub-id-type="pmid">17287812</pub-id>
</element-citation>
</ref>
<ref id="B28-cells-08-00255">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cherfils</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zeghouf</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Regulation of small GTPases by GEFs, GAPs, and GDIs</article-title>
<source/>Physiol. Rev.
          <year>2013</year>
<volume>93</volume>
<fpage>269</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00003.2012</pub-id>
<pub-id pub-id-type="pmid">23303910</pub-id>
</element-citation>
</ref>
<ref id="B29-cells-08-00255">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dworak</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Makosa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jividen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Snow</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Simke</surname>
<given-names>W.C.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>I.G.</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Paschal</surname>
<given-names>B.M.</given-names>
</name>
</person-group>
<article-title>A nuclear lamina-chromatin-Ran GTPase axis modulates nuclear import and DNA damage signaling</article-title>
<source/>Aging Cell
          <year>2019</year>
<volume>18</volume>
<fpage>e12851</fpage>
<pub-id pub-id-type="doi">10.1111/acel.12851</pub-id>
<pub-id pub-id-type="pmid">30565836</pub-id>
</element-citation>
</ref>
<ref id="B30-cells-08-00255">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yudin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fainzilber</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Ran on tracks-cytoplasmic roles for a nuclear regulator</article-title>
<source/>J. Cell Sci.
          <year>2009</year>
<volume>122</volume>
<fpage>587</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.015289</pub-id>
<pub-id pub-id-type="pmid">19225125</pub-id>
</element-citation>
</ref>
<ref id="B31-cells-08-00255">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Knockdown of Ran GTPase expression inhibits the proliferation and migration of breast cancer cells</article-title>
<source/>Mol. Med. Rep.
          <year>2018</year>
<volume>18</volume>
<fpage>157</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.3892/mmr.2018.8952</pub-id>
<pub-id pub-id-type="pmid">29750309</pub-id>
</element-citation>
</ref>
<ref id="B32-cells-08-00255">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klosowiak</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Focia</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Chakravarthy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Landahl</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Freymann</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Structural coupling of the EF hand and C-terminal GTPase domains in the mitochondrial protein Miro</article-title>
<source/>EMBO Rep.
          <year>2013</year>
<volume>14</volume>
<fpage>968</fpage>
<lpage>974</lpage>
<pub-id pub-id-type="doi">10.1038/embor.2013.151</pub-id>
<pub-id pub-id-type="pmid">24071720</pub-id>
</element-citation>
</ref>
<ref id="B33-cells-08-00255">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>The myriad roles of Miro in the nervous system: Axonal transport of mitochondria and beyond</article-title>
<source/>Front. Cell. Neurosci.
          <year>2014</year>
<volume>8</volume>
<fpage>330</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2014.00330</pub-id>
<pub-id pub-id-type="pmid">25389385</pub-id>
</element-citation>
</ref>
<ref id="B34-cells-08-00255">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cromm</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grossmann</surname>
<given-names>T.N.</given-names>
</name>
<name>
<surname>Waldmann</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Direct modulation of small GTPase activity and function</article-title>
<source/>Angew. Chem. Int. Ed.
          <year>2015</year>
<volume>54</volume>
<fpage>13516</fpage>
<lpage>13537</lpage>
<pub-id pub-id-type="doi">10.1002/anie.201504357</pub-id>
<pub-id pub-id-type="pmid">26470842</pub-id>
</element-citation>
</ref>
<ref id="B35-cells-08-00255">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cox</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Fesik</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Kimmelman</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Der</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Drugging the undruggable RAS: Mission possible?</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2014</year>
<volume>13</volume>
<fpage>828</fpage>
<lpage>851</lpage>
<pub-id pub-id-type="doi">10.1038/nrd4389</pub-id>
<pub-id pub-id-type="pmid">25323927</pub-id>
</element-citation>
</ref>
<ref id="B36-cells-08-00255">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Approaches of targeting Rho GTPases in cancer drug discovery</article-title>
<source/>Expert Opin. Drug Discov.
          <year>2015</year>
<volume>10</volume>
<fpage>991</fpage>
<lpage>1010</lpage>
<pub-id pub-id-type="doi">10.1517/17460441.2015.1058775</pub-id>
<pub-id pub-id-type="pmid">26087073</pub-id>
</element-citation>
</ref>
<ref id="B37-cells-08-00255">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flisiak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zeeh</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Guibert</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cherfils</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zeghouf</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>An Arf1 GTPase mutant with different responses to GEF inhibitors</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2008</year>
<volume>377</volume>
<fpage>156</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2008.09.107</pub-id>
<pub-id pub-id-type="pmid">18834864</pub-id>
</element-citation>
</ref>
<ref id="B38-cells-08-00255">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chavanieu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>58111</fpage>
<lpage>58120</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.11185</pub-id>
<pub-id pub-id-type="pmid">27517156</pub-id>
</element-citation>
</ref>
<ref id="B39-cells-08-00255">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>C.E.</given-names>
</name>
</person-group>
<article-title>Paxillin interactions</article-title>
<source/>J. Cell Sci.
          <year>2000</year>
<volume>113</volume>
<fpage>4139</fpage>
<lpage>4140</lpage>
<pub-id pub-id-type="pmid">11069756</pub-id>
</element-citation>
</ref>
<ref id="B40-cells-08-00255">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourgoin</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>El Azreq</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Small inhibitors of ADP-ribosylation factor activation and function in mammalian cells</article-title>
<source/>World J. Pharmacol.
          <year>2012</year>
<volume>1</volume>
<fpage>55</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.5497/wjp.v1.i4.55</pub-id>
</element-citation>
</ref>
<ref id="B41-cells-08-00255">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spooner</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Boal</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Amessou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Johannes</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Clarkson</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>The secretion inhibitor Exo2 perturbs trafficking of Shiga toxin between endosomes and the <italic>trans</italic>-Golgi network</article-title>
<source/>Biochem. J.
          <year>2008</year>
<volume>414</volume>
<fpage>471</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20080149</pub-id>
<pub-id pub-id-type="pmid">18522538</pub-id>
</element-citation>
</ref>
<ref id="B42-cells-08-00255">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sorieul</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Langhans</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guetzoyan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hillmer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Clarkson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Spooner</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Frigerio</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>An Exo2 derivative affects ER and Golgi morphology and vacuolar sorting in a tissue-specific manner in <italic>Arabidopsis</italic></article-title>
<source/>Traffic
          <year>2011</year>
<volume>12</volume>
<fpage>1552</fpage>
<lpage>1562</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-0854.2011.01258.x</pub-id>
<pub-id pub-id-type="pmid">21801289</pub-id>
</element-citation>
</ref>
<ref id="B43-cells-08-00255">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pauloin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Adenot</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hue-Beauvais</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chanat</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>The perilipin-2 (adipophilin) coat of cytosolic lipid droplets is regulated by an Arf1-dependent mechanism in HC11 mouse mammary epithelial cells</article-title>
<source/>Cell Biol. Int.
          <year>2016</year>
<volume>40</volume>
<fpage>143</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1002/cbin.10547</pub-id>
<pub-id pub-id-type="pmid">26399370</pub-id>
</element-citation>
</ref>
<ref id="B44-cells-08-00255">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shay</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics</article-title>
<source/>J. Exp. Clin. Cancer Res.
          <year>2017</year>
<volume>36</volume>
<fpage>112</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-017-0583-4</pub-id>
<pub-id pub-id-type="pmid">28830537</pub-id>
</element-citation>
</ref>
<ref id="B45-cells-08-00255">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shay</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis</article-title>
<source/>J. Exp. Clin. Cancer Res.
          <year>2019</year>
<volume>38</volume>
<fpage>84</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-019-1080-8</pub-id>
<pub-id pub-id-type="pmid">30777099</pub-id>
</element-citation>
</ref>
<ref id="B46-cells-08-00255">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mossessova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Corpina</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Crystal structure of ARF1•Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism</article-title>
<source/>Mol. Cell
          <year>2003</year>
<volume>12</volume>
<fpage>1403</fpage>
<lpage>1411</lpage>
<pub-id pub-id-type="doi">10.1016/S1097-2765(03)00475-1</pub-id>
<pub-id pub-id-type="pmid">14690595</pub-id>
</element-citation>
</ref>
<ref id="B47-cells-08-00255">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vigil</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cherfils</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rossman</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Der</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Ras superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy?</article-title>
<source/>Nat. Rev. Cancer
          <year>2010</year>
<volume>10</volume>
<fpage>842</fpage>
<lpage>857</lpage>
<pub-id pub-id-type="doi">10.1038/nrc2960</pub-id>
<pub-id pub-id-type="pmid">21102635</pub-id>
</element-citation>
</ref>
<ref id="B48-cells-08-00255">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeeh</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Zeghouf</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grauffel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guibert</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dejaegere</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cherfils</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Dual specificity of the interfacial inhibitor Brefeldin A for Arf proteins and Sec7 domains</article-title>
<source/>J. Biol. Chem.
          <year>2006</year>
<volume>281</volume>
<fpage>11805</fpage>
<lpage>11814</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M600149200</pub-id>
<pub-id pub-id-type="pmid">16484231</pub-id>
</element-citation>
</ref>
<ref id="B49-cells-08-00255">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawato</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kadin</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Higashihara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kunisada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Umezawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Horie</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines</article-title>
<source/>Br. J. Haematol.
          <year>2015</year>
<volume>170</volume>
<fpage>837</fpage>
<lpage>846</lpage>
<pub-id pub-id-type="doi">10.1111/bjh.13508</pub-id>
<pub-id pub-id-type="pmid">26105086</pub-id>
</element-citation>
</ref>
<ref id="B50-cells-08-00255">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anadu</surname>
<given-names>N.O.</given-names>
</name>
<name>
<surname>Davisson</surname>
<given-names>V.J.</given-names>
</name>
<name>
<surname>Cushman</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Synthesis and anticancer activity of Brefeldin A ester derivatives</article-title>
<source/>J. Med. Chem.
          <year>2006</year>
<volume>49</volume>
<fpage>3897</fpage>
<lpage>3905</lpage>
<pub-id pub-id-type="doi">10.1021/jm0602817</pub-id>
<pub-id pub-id-type="pmid">16789745</pub-id>
</element-citation>
</ref>
<ref id="B51-cells-08-00255">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Synthesis and cytotoxic evaluation of acylated Brefeldin A derivatives as potential anticancer agents</article-title>
<source/>Chem. Biol. Drug Des.
          <year>2013</year>
<volume>82</volume>
<fpage>307</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1111/cbdd.12154</pub-id>
<pub-id pub-id-type="pmid">23621857</pub-id>
</element-citation>
</ref>
<ref id="B52-cells-08-00255">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seehafer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rominger</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Helmchen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Langhans</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Özata</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Brügger</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Strating</surname>
<given-names>J.R.P.M.</given-names>
</name>
<name>
<surname>Van Kuppeveld</surname>
<given-names>F.J.M.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>Synthesis and biological properties of novel Brefeldin A analogues</article-title>
<source/>J. Med. Chem.
          <year>2013</year>
<volume>56</volume>
<fpage>5872</fpage>
<lpage>5884</lpage>
<pub-id pub-id-type="doi">10.1021/jm400615g</pub-id>
<pub-id pub-id-type="pmid">23805957</pub-id>
</element-citation>
</ref>
<ref id="B53-cells-08-00255">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiina</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Umezaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamori</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Total synthesis of AMF-26, an antitumor agent for inhibition of the Golgi system, targeting ADP-ribosylation factor 1</article-title>
<source/>J. Med. Chem.
          <year>2013</year>
<volume>56</volume>
<fpage>150</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="doi">10.1021/jm301695c</pub-id>
<pub-id pub-id-type="pmid">23214926</pub-id>
</element-citation>
</ref>
<ref id="B54-cells-08-00255">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamaotsu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hirono</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamori</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy</article-title>
<source/>J. Biol. Chem.
          <year>2012</year>
<volume>287</volume>
<fpage>3885</fpage>
<lpage>3897</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.316125</pub-id>
<pub-id pub-id-type="pmid">22158626</pub-id>
</element-citation>
</ref>
<ref id="B55-cells-08-00255">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hirosawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tamaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Akatsuka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Yoshimatsu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shiina</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Yamori</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>M-COPA, a Golgi disruptor, inhibits cell surface expression of MET protein and exhibits antitumor activity against MET-addicted gastric cancers</article-title>
<source/>Cancer Res.
          <year>2016</year>
<volume>76</volume>
<fpage>3895</fpage>
<lpage>3903</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2220</pub-id>
<pub-id pub-id-type="pmid">27197184</pub-id>
</element-citation>
</ref>
<ref id="B56-cells-08-00255">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watari</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukunaga</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Furuno</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hosoi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kuwano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kuwano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-κB pathway</article-title>
<source/>Int. J. Cancer
          <year>2012</year>
<volume>131</volume>
<fpage>310</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.26356</pub-id>
<pub-id pub-id-type="pmid">21826646</pub-id>
</element-citation>
</ref>
<ref id="B57-cells-08-00255">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Obata</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Horikawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tasaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shiina</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells</article-title>
<source/>PLoS ONE
          <year>2017</year>
<volume>12</volume>
<elocation-id>e0175514</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0175514</pub-id>
<pub-id pub-id-type="pmid">28403213</pub-id>
</element-citation>
</ref>
<ref id="B58-cells-08-00255">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hattori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Watanabe-Takahashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shiina</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Naito</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin</article-title>
<source/>Genes Cells
          <year>2016</year>
<volume>21</volume>
<fpage>901</fpage>
<lpage>906</lpage>
<pub-id pub-id-type="doi">10.1111/gtc.12386</pub-id>
<pub-id pub-id-type="pmid">27302278</pub-id>
</element-citation>
</ref>
<ref id="B59-cells-08-00255">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hayallah</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Famulok</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Affinity-based labeling of cytohesins with a bifunctional SecinH3 photoaffinity probe</article-title>
<source/>Angew. Chem. Int. Ed.
          <year>2008</year>
<volume>47</volume>
<fpage>9565</fpage>
<lpage>9568</lpage>
<pub-id pub-id-type="doi">10.1002/anie.200803962</pub-id>
</element-citation>
</ref>
<ref id="B60-cells-08-00255">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hafner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grüne</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Srivatsan</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kolanus</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Quast</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kremmer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Famulok</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance</article-title>
<source/>Nature
          <year>2006</year>
<volume>444</volume>
<fpage>941</fpage>
<lpage>944</lpage>
<pub-id pub-id-type="doi">10.1038/nature05415</pub-id>
<pub-id pub-id-type="pmid">17167487</pub-id>
</element-citation>
</ref>
<ref id="B61-cells-08-00255">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayaram</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Syed</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kyathanahalli</surname>
<given-names>C.N.</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Kowluru</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Arf nucleotide binding site opener [ARNO] promotes sequential activation of Arf6, Cdc42 and Rac1 and insulin secretion in INS 832/13 β-cells and rat islets</article-title>
<source/>Biochem. Pharmacol.
          <year>2011</year>
<volume>81</volume>
<fpage>1016</fpage>
<lpage>1027</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2011.01.006</pub-id>
<pub-id pub-id-type="pmid">21276423</pub-id>
</element-citation>
</ref>
<ref id="B62-cells-08-00255">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Humphreys</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Hume</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Koronakis</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The Arf GTPase-activating protein family is exploited by Salmonella enterica serovar Typhimurium to invade nonphagocytic host cells</article-title>
<source/>MBio
          <year>2015</year>
<volume>6</volume>
<fpage>e02253-14</fpage>
<pub-id pub-id-type="doi">10.1128/mBio.02253-14</pub-id>
<pub-id pub-id-type="pmid">25670778</pub-id>
</element-citation>
</ref>
<ref id="B63-cells-08-00255">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ahirwar</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Oghumu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wilkie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Nasser</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Satoskar</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.Y.</given-names>
</name>
<name>
<surname>Ganju</surname>
<given-names>R.K.</given-names>
</name>
</person-group>
<article-title>Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis</article-title>
<source/>Mol. Oncol.
          <year>2016</year>
<volume>10</volume>
<fpage>272</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1016/j.molonc.2015.10.007</pub-id>
<pub-id pub-id-type="pmid">26778715</pub-id>
</element-citation>
</ref>
<ref id="B64-cells-08-00255">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bill</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>König</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Heukamp</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Hannam</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Famulok</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<elocation-id>e41179</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0041179</pub-id>
<pub-id pub-id-type="pmid">22815959</pub-id>
</element-citation>
</ref>
<ref id="B65-cells-08-00255">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cytohesins/ARNO: The function in colorectal cancer cells</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<elocation-id>e90997</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0090997</pub-id>
<pub-id pub-id-type="pmid">24618737</pub-id>
</element-citation>
</ref>
<ref id="B66-cells-08-00255">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Germer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>RNA aptamers and their therapeutic and diagnostic applications</article-title>
<source/>Int. J. Biochem. Mol. Biol.
          <year>2013</year>
<volume>4</volume>
<fpage>27</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">23638319</pub-id>
</element-citation>
</ref>
<ref id="B67-cells-08-00255">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Blind</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nagel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Böhm</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Knorr</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Kolanus</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Famulok</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Controlling small guanine-nucleotide-exchange factor function through cytoplasmic RNA intramers</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2001</year>
<volume>98</volume>
<fpage>4961</fpage>
<lpage>4965</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.091100698</pub-id>
<pub-id pub-id-type="pmid">11320245</pub-id>
</element-citation>
</ref>
<ref id="B68-cells-08-00255">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Hattum</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Waldmann</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Chemical biology tools for regulating RAS signaling complexity in space and time</article-title>
<source/>Chem. Biol.
          <year>2014</year>
<volume>21</volume>
<fpage>1185</fpage>
<lpage>1195</lpage>
<pub-id pub-id-type="doi">10.1016/j.chembiol.2014.08.001</pub-id>
<pub-id pub-id-type="pmid">25237862</pub-id>
</element-citation>
</ref>
<ref id="B69-cells-08-00255">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rudolph</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Ras inhibition via direct Ras binding-is there a path forward?</article-title>
<source/>Bioorg. Med. Chem. Lett.
          <year>2012</year>
<volume>22</volume>
<fpage>5766</fpage>
<lpage>5776</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmcl.2012.07.082</pub-id>
<pub-id pub-id-type="pmid">22902659</pub-id>
</element-citation>
</ref>
<ref id="B70-cells-08-00255">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spencer-Smith</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Koide</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Koide</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>O’Bryan</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Targeting the α4-α5 interface of RAS results in multiple levels of inhibition</article-title>
<source/>Small GTPases
          <year>2018</year>
<comment>in press</comment>
<pub-id pub-id-type="doi">10.1080/21541248.2017.1333188</pub-id>
</element-citation>
</ref>
<ref id="B71-cells-08-00255">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patgiri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Bar-Sagi</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>An orthosteric inhibitor of the Ras-Sos interaction</article-title>
<source/>Nat. Chem. Biol.
          <year>2011</year>
<volume>7</volume>
<fpage>585</fpage>
<lpage>587</lpage>
<pub-id pub-id-type="doi">10.1038/nchembio.612</pub-id>
<pub-id pub-id-type="pmid">21765406</pub-id>
</element-citation>
</ref>
<ref id="B72-cells-08-00255">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nussinov</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Inhibitors of Ras-SOS interactions</article-title>
<source/>ChemMedChem
          <year>2016</year>
<volume>11</volume>
<fpage>814</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1002/cmdc.201500481</pub-id>
<pub-id pub-id-type="pmid">26630662</pub-id>
</element-citation>
</ref>
<ref id="B73-cells-08-00255">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schöpel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jockers</surname>
<given-names>K.F.</given-names>
</name>
<name>
<surname>Düppe</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Autzen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Potheraveedu</surname>
<given-names>V.N.</given-names>
</name>
<name>
<surname>Ince</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yip</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Heumann</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Scherkenbeck</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bisphenol A binds to Ras proteins and competes with guanine nucleotide exchange: Implications for GTPase-selective antagonists</article-title>
<source/>J. Med. Chem.
          <year>2013</year>
<volume>56</volume>
<fpage>9664</fpage>
<lpage>9672</lpage>
<pub-id pub-id-type="doi">10.1021/jm401291q</pub-id>
<pub-id pub-id-type="pmid">24266771</pub-id>
</element-citation>
</ref>
<ref id="B74-cells-08-00255">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Airoldi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Martegani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>van Neuren</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marinzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nicotra</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Design, synthesis and biological evaluation of sugar-derived Ras inhibitors</article-title>
<source/>ChemBioChem
          <year>2005</year>
<volume>6</volume>
<fpage>1839</fpage>
<lpage>1848</lpage>
<pub-id pub-id-type="doi">10.1002/cbic.200400420</pub-id>
<pub-id pub-id-type="pmid">16196015</pub-id>
</element-citation>
</ref>
<ref id="B75-cells-08-00255">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leshchiner</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Parkhitko</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>G.H.</given-names>
</name>
<name>
<surname>Luccarelli</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bellairs</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Escudero</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Opoku-Nsiah</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Godes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perrimon</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Walensky</surname>
<given-names>L.D.</given-names>
</name>
</person-group>
<article-title>Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2015</year>
<volume>112</volume>
<fpage>1761</fpage>
<lpage>1766</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1413185112</pub-id>
<pub-id pub-id-type="pmid">25624485</pub-id>
</element-citation>
</ref>
<ref id="B76-cells-08-00255">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taveras</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Remiszewski</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Doll</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Cesarz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Kirschmeier</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pramanik</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Snow</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>del Rosario</surname>
<given-names>J.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ras oncoprotein inhibitors: The discovery of potent, Ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex</article-title>
<source/>Bioorg. Med. Chem.
          <year>1997</year>
<volume>5</volume>
<fpage>125</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1016/S0968-0896(96)00202-7</pub-id>
<pub-id pub-id-type="pmid">9043664</pub-id>
</element-citation>
</ref>
<ref id="B77-cells-08-00255">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganguly</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Pramanik</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Doll</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Snow</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Taveras</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Remiszewski</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cesarz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>del Rosario</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vibulbhan</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interaction of a novel GDP exchange inhibitor with the Ras protein</article-title>
<source/>Biochemistry
          <year>1998</year>
<volume>37</volume>
<fpage>15631</fpage>
<lpage>15637</lpage>
<pub-id pub-id-type="doi">10.1021/bi9805691</pub-id>
<pub-id pub-id-type="pmid">9843367</pub-id>
</element-citation>
</ref>
<ref id="B78-cells-08-00255">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmioli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Di Domizio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Gioia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gaponenko</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Vanoni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peri</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand</article-title>
<source/>Bioorg. Med. Chem. Lett.
          <year>2009</year>
<volume>19</volume>
<fpage>4217</fpage>
<lpage>4222</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmcl.2009.05.107</pub-id>
<pub-id pub-id-type="pmid">19515561</pub-id>
</element-citation>
</ref>
<ref id="B79-cells-08-00255">
<label>79.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Kalbitzer</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Spoerner</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>State 1(T) inhibitors of activated Ras</article-title>
<source/>Inhibitors of the Ras Superfamily G-Proteins, Part A
          <person-group person-group-type="editor">
<name>
<surname>Tamanoi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<publisher-name>Elsevier Inc.</publisher-name>
<publisher-loc>Amsterdam, The Netherlands</publisher-loc>
<year>2013</year>
<volume>Volume 33</volume>
<fpage>69</fpage>
<lpage>94</lpage>
<isbn>9780124167490</isbn>
</element-citation>
</ref>
<ref id="B80-cells-08-00255">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spoerner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>König</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kalbitzer</surname>
<given-names>H.R.</given-names>
</name>
</person-group>
<article-title>A novel mechanism for the modulation of the Ras-effector interaction by small molecules</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2005</year>
<volume>334</volume>
<fpage>709</fpage>
<lpage>713</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2005.06.144</pub-id>
<pub-id pub-id-type="pmid">16036132</pub-id>
</element-citation>
</ref>
<ref id="B81-cells-08-00255">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosnizeck</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Spoerner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tränkle</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Filchtinski</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gremer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vetter</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Wittinghofer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>König</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Stabilizing a weak binding state for effectors in the human Ras protein by cyclen complexes</article-title>
<source/>Angew. Chem. Int. Ed.
          <year>2010</year>
<volume>49</volume>
<fpage>3830</fpage>
<lpage>3833</lpage>
<pub-id pub-id-type="doi">10.1002/anie.200907002</pub-id>
</element-citation>
</ref>
<ref id="B82-cells-08-00255">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.M.D.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>D.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts <italic>in vivo</italic> by an enantiomeric iridium(III) metal-based compound</article-title>
<source/>Chem. Sci.
          <year>2017</year>
<volume>8</volume>
<fpage>4756</fpage>
<lpage>4763</lpage>
<pub-id pub-id-type="doi">10.1039/C7SC00311K</pub-id>
<pub-id pub-id-type="pmid">28959398</pub-id>
</element-citation>
</ref>
<ref id="B83-cells-08-00255">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kauke</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Traxlmayr</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Kiefer</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Knihtila</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>McGee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Verdine</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mattos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wittrup</surname>
<given-names>K.D.</given-names>
</name>
</person-group>
<article-title>An engineered protein antagonist of K-Ras/B-Raf interaction</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>5831</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-05889-7</pub-id>
<pub-id pub-id-type="pmid">28724936</pub-id>
</element-citation>
</ref>
<ref id="B84-cells-08-00255">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Block</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Geisen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Winde</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Möröy</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Sulindac sulfide inhibits Ras signaling</article-title>
<source/>Oncogene
          <year>1998</year>
<volume>17</volume>
<fpage>1769</fpage>
<lpage>1776</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1202085</pub-id>
<pub-id pub-id-type="pmid">9778042</pub-id>
</element-citation>
</ref>
<ref id="B85-cells-08-00255">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilad</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Bresler</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gnainsky</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Smirnoff</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells</article-title>
<source/>J. Endocrinol.
          <year>2005</year>
<volume>185</volume>
<fpage>577</fpage>
<lpage>592</lpage>
<pub-id pub-id-type="doi">10.1677/joe.1.05770</pub-id>
<pub-id pub-id-type="pmid">15930183</pub-id>
</element-citation>
</ref>
<ref id="B86-cells-08-00255">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>W.C.</given-names>
</name>
</person-group>
<article-title>Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases</article-title>
<source/>Cell. Signal.
          <year>2008</year>
<volume>20</volume>
<fpage>1134</fpage>
<lpage>1141</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2008.02.004</pub-id>
<pub-id pub-id-type="pmid">18374541</pub-id>
</element-citation>
</ref>
<ref id="B87-cells-08-00255">
<label>87.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Khazak</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Eyrisch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tamanoi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Golemis</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>A two-hybrid approach to identify inhibitors of the RAS-RAF interaction</article-title>
<source/>Inhibitors of the Ras Superfamily G-Proteins, Part A
          <person-group person-group-type="editor">
<name>
<surname>Tamanoi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<publisher-name>Elsevier Inc.</publisher-name>
<publisher-loc>Amsterdam, The Netherlands</publisher-loc>
<year>2013</year>
<volume>Volume 33</volume>
<fpage>213</fpage>
<lpage>248</lpage>
<isbn>9780124167490</isbn>
</element-citation>
</ref>
<ref id="B88-cells-08-00255">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skobeleva</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Golemis</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Khazak</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors</article-title>
<source/>Mol. Cancer Ther.
          <year>2007</year>
<volume>6</volume>
<fpage>898</fpage>
<lpage>906</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0602</pub-id>
<pub-id pub-id-type="pmid">17363484</pub-id>
</element-citation>
</ref>
<ref id="B89-cells-08-00255">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oinuma</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Negishi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Semaphorin 4D/Plexin-B1–mediated R-Ras GAP activity inhibits cell migration by regulating β1 integrin activity</article-title>
<source/>J. Cell Biol.
          <year>2006</year>
<volume>173</volume>
<fpage>601</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200508204</pub-id>
<pub-id pub-id-type="pmid">16702230</pub-id>
</element-citation>
</ref>
<ref id="B90-cells-08-00255">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Endo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Inactivation of Ras by p120GAP via focal adhesion kinase dephosphorylation mediates RGMa-induced growth cone collapse</article-title>
<source/>J. Neurosci.
          <year>2009</year>
<volume>29</volume>
<fpage>6649</fpage>
<lpage>6662</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0927-09.2009</pub-id>
<pub-id pub-id-type="pmid">19458235</pub-id>
</element-citation>
</ref>
<ref id="B91-cells-08-00255">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oinuma</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Negishi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The semaphorin 4D receptor plexin-B1 is a GTPase activating protein for R-Ras</article-title>
<source/>Science
          <year>2004</year>
<volume>305</volume>
<fpage>862</fpage>
<lpage>865</lpage>
<pub-id pub-id-type="doi">10.1126/science.1097545</pub-id>
<pub-id pub-id-type="pmid">15297673</pub-id>
</element-citation>
</ref>
<ref id="B92-cells-08-00255">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quah</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Teh</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Stanslas</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs</article-title>
<source/>Pharmacol. Ther.
          <year>2016</year>
<volume>162</volume>
<fpage>35</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2016.03.010</pub-id>
<pub-id pub-id-type="pmid">27016467</pub-id>
</element-citation>
</ref>
<ref id="B93-cells-08-00255">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laheru</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rajeshkumar</surname>
<given-names>N.V.</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Goldsweig</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>D.T.</given-names>
</name>
<name>
<surname>Donehower</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jimeno</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Linden</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer</article-title>
<source/>Investig. New Drugs
          <year>2012</year>
<volume>30</volume>
<fpage>2391</fpage>
<lpage>2399</lpage>
<pub-id pub-id-type="doi">10.1007/s10637-012-9818-6</pub-id>
<pub-id pub-id-type="pmid">22547163</pub-id>
</element-citation>
</ref>
<ref id="B94-cells-08-00255">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haklai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Elad-Sfadia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Egozi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kloog</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice</article-title>
<source/>Cancer Chemother. Pharmacol.
          <year>2008</year>
<volume>61</volume>
<fpage>89</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1007/s00280-007-0451-6</pub-id>
<pub-id pub-id-type="pmid">17909812</pub-id>
</element-citation>
</ref>
<ref id="B95-cells-08-00255">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zundelevich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Elad-Sfadia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Haklai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kloog</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)</article-title>
<source/>Mol. Cancer Ther.
          <year>2007</year>
<volume>6</volume>
<fpage>1765</fpage>
<lpage>1773</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0706</pub-id>
<pub-id pub-id-type="pmid">17541036</pub-id>
</element-citation>
</ref>
<ref id="B96-cells-08-00255">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charette</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>De Saeger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lannoy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Horsmans</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Leclercq</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Stärkel</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through Ras and mTOR inhibition</article-title>
<source/>Mol. Cancer
          <year>2010</year>
<volume>9</volume>
<fpage>256</fpage>
<pub-id pub-id-type="doi">10.1186/1476-4598-9-256</pub-id>
<pub-id pub-id-type="pmid">20860815</pub-id>
</element-citation>
</ref>
<ref id="B97-cells-08-00255">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McPherson</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Conaway</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Santen</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro</article-title>
<source/>Prostate
          <year>2004</year>
<volume>58</volume>
<fpage>325</fpage>
<lpage>334</lpage>
<pub-id pub-id-type="doi">10.1002/pros.10336</pub-id>
<pub-id pub-id-type="pmid">14968433</pub-id>
</element-citation>
</ref>
<ref id="B98-cells-08-00255">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riely</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Medina</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rizvi</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>V.A.</given-names>
</name>
<name>
<surname>Kris</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Pietanza</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Azzoli</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Krug</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Pao</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations</article-title>
<source/>J. Thorac. Oncol.
          <year>2011</year>
<volume>6</volume>
<fpage>1435</fpage>
<lpage>1437</lpage>
<pub-id pub-id-type="doi">10.1097/JTO.0b013e318223c099</pub-id>
<pub-id pub-id-type="pmid">21847063</pub-id>
</element-citation>
</ref>
<ref id="B99-cells-08-00255">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berndt</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Sebti</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Targeting protein prenylation for cancer therapy</article-title>
<source/>Nat. Rev. Cancer
          <year>2011</year>
<volume>11</volume>
<fpage>775</fpage>
<lpage>791</lpage>
<pub-id pub-id-type="doi">10.1038/nrc3151</pub-id>
<pub-id pub-id-type="pmid">22020205</pub-id>
</element-citation>
</ref>
<ref id="B100-cells-08-00255">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>N.W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kendirli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Lander</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras</article-title>
<source/>Cell
          <year>2017</year>
<volume>168</volume>
<fpage>890</fpage>
<lpage>903</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.01.013</pub-id>
<pub-id pub-id-type="pmid">28162770</pub-id>
</element-citation>
</ref>
<ref id="B101-cells-08-00255">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heid</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lubeseder-Martellato</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sipos</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mazur</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Lesina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Siveke</surname>
<given-names>J.T.</given-names>
</name>
</person-group>
<article-title>Early requirement of Rac1 in a mouse model of pancreatic cancer</article-title>
<source/>Gastroenterology
          <year>2011</year>
<volume>141</volume>
<fpage>719</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2011.04.043</pub-id>
<pub-id pub-id-type="pmid">21684285</pub-id>
</element-citation>
</ref>
<ref id="B102-cells-08-00255">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Hancock</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Molina-Arcas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Steckel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>East</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Diefenbacher</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Armenteros-Monterroso</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lassailly</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nye</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer</article-title>
<source/>Cell
          <year>2012</year>
<volume>149</volume>
<fpage>642</fpage>
<lpage>655</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2012.02.059</pub-id>
<pub-id pub-id-type="pmid">22541434</pub-id>
</element-citation>
</ref>
<ref id="B103-cells-08-00255">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Toda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Targeting metabolic reprogramming in KRAS-driven cancers</article-title>
<source/>Int. J. Clin. Oncol.
          <year>2017</year>
<volume>22</volume>
<fpage>651</fpage>
<lpage>659</lpage>
<pub-id pub-id-type="doi">10.1007/s10147-017-1156-4</pub-id>
<pub-id pub-id-type="pmid">28647837</pub-id>
</element-citation>
</ref>
<ref id="B104-cells-08-00255">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takakura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Waldron</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Hines</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice</article-title>
<source/>PLoS ONE
          <year>2017</year>
<volume>12</volume>
<elocation-id>e0184455</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0184455</pub-id>
<pub-id pub-id-type="pmid">28886117</pub-id>
</element-citation>
</ref>
<ref id="B105-cells-08-00255">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lock</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kenific</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Salas</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ronen</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Debnath</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation</article-title>
<source/>Mol. Biol. Cell
          <year>2011</year>
<volume>22</volume>
<fpage>165</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.e10-06-0500</pub-id>
<pub-id pub-id-type="pmid">21119005</pub-id>
</element-citation>
</ref>
<ref id="B106-cells-08-00255">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Mathew</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Strohecker</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Karsli-Uzunbas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kamphorst</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lemons</surname>
<given-names>J.M.S.</given-names>
</name>
<name>
<surname>Karantza</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis</article-title>
<source/>Genes Dev.
          <year>2011</year>
<volume>25</volume>
<fpage>460</fpage>
<lpage>470</lpage>
<pub-id pub-id-type="doi">10.1101/gad.2016311</pub-id>
<pub-id pub-id-type="pmid">21317241</pub-id>
</element-citation>
</ref>
<ref id="B107-cells-08-00255">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mack</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Whalley</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Castillo-Lluva</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Malliri</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The diverse roles of Rac signaling in tumorigenesis</article-title>
<source/>Cell Cycle
          <year>2011</year>
<volume>10</volume>
<fpage>1571</fpage>
<lpage>1581</lpage>
<pub-id pub-id-type="doi">10.4161/cc.10.10.15612</pub-id>
<pub-id pub-id-type="pmid">21478669</pub-id>
</element-citation>
</ref>
<ref id="B108-cells-08-00255">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Rational design and characterization of a Rac GTPase-specific small molecule inhibitor</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2004</year>
<volume>101</volume>
<fpage>7618</fpage>
<lpage>7623</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0307512101</pub-id>
<pub-id pub-id-type="pmid">15128949</pub-id>
</element-citation>
</ref>
<ref id="B109-cells-08-00255">
<label>109.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Akbar</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cancelas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Rational design and applications of a Rac GTPase-specific small molecule inhibitor</article-title>
<source/>Regulators and Effectors of Small GTPases: Rho Family
          <person-group person-group-type="editor">
<name>
<surname>Balch</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Der</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>A.</given-names>
</name>
</person-group>
<publisher-name>Elsevier Inc.</publisher-name>
<publisher-loc>Amsterdam, The Netherlands</publisher-loc>
<year>2006</year>
<volume>Volume 406</volume>
<fpage>554</fpage>
<lpage>565</lpage>
</element-citation>
</ref>
<ref id="B110-cells-08-00255">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaneto</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Saiki</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer</article-title>
<source/>Cancer Sci.
          <year>2014</year>
<volume>105</volume>
<fpage>788</fpage>
<lpage>794</lpage>
<pub-id pub-id-type="doi">10.1111/cas.12425</pub-id>
<pub-id pub-id-type="pmid">24750242</pub-id>
</element-citation>
</ref>
<ref id="B111-cells-08-00255">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hein</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Etekpo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Burchett</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Enke</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Batra</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Cowan</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Ouellette</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation</article-title>
<source/>Oncotarget
          <year>2014</year>
<volume>5</volume>
<fpage>10251</fpage>
<lpage>10270</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.2500</pub-id>
<pub-id pub-id-type="pmid">25344910</pub-id>
</element-citation>
</ref>
<ref id="B112-cells-08-00255">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernández</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>de la Mota-Peynado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dharmawardhane</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vlaar</surname>
<given-names>C.P.</given-names>
</name>
</person-group>
<article-title>Novel inhibitors of Rac1 in metastatic breast cancer</article-title>
<source/>P. R. Health Sci. J.
          <year>2010</year>
<volume>29</volume>
<fpage>348</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="pmid">21261173</pub-id>
</element-citation>
</ref>
<ref id="B113-cells-08-00255">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montalvo-Ortiz</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Castillo-Pichardo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hernández</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Humphries-Bickley</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>de la Mota-Peynado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cubano</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Vlaar</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Dharmawardhane</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase</article-title>
<source/>J. Biol. Chem.
          <year>2012</year>
<volume>287</volume>
<fpage>13228</fpage>
<lpage>13238</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.334524</pub-id>
<pub-id pub-id-type="pmid">22383527</pub-id>
</element-citation>
</ref>
<ref id="B114-cells-08-00255">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castillo-Pichardo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Humphries-Bickley</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>de la Parra</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Forestier-Roman</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Martinez-Ferrer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vlaar</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ferrer-Acosta</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Washington</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Cubano</surname>
<given-names>L.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Rac inhibitor EHop-016 inhibits mammary tumor growth and metastasis in a nude mouse model</article-title>
<source/>Transl. Oncol.
          <year>2014</year>
<volume>7</volume>
<fpage>546</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1016/j.tranon.2014.07.004</pub-id>
<pub-id pub-id-type="pmid">25389450</pub-id>
</element-citation>
</ref>
<ref id="B115-cells-08-00255">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mali</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ramdas</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Munugalavadla</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mattingly</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Visconte</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pak and Rac GTPases promote oncogenic KIT-induced neoplasms</article-title>
<source/>J. Clin. Investig.
          <year>2013</year>
<volume>123</volume>
<fpage>4449</fpage>
<lpage>4463</lpage>
<pub-id pub-id-type="doi">10.1172/JCI67509</pub-id>
<pub-id pub-id-type="pmid">24091327</pub-id>
</element-citation>
</ref>
<ref id="B116-cells-08-00255">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>L.X.</given-names>
</name>
<name>
<surname>Agaram</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mimae</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>López-Lago</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>M.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrin-α10 dependency identifies RAC and RICTOR as therapeutic targets in high-grade myxofibrosarcoma</article-title>
<source/>Cancer Discov.
          <year>2016</year>
<volume>6</volume>
<fpage>1148</fpage>
<lpage>1165</lpage>
<pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-1481</pub-id>
<pub-id pub-id-type="pmid">27577794</pub-id>
</element-citation>
</ref>
<ref id="B117-cells-08-00255">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veluthakal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tunduguru</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Sidarala</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Syeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vlaar</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Turmond</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Kowluru</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>VAV2, a guanine nucleotide exchange factor for Rac1, regulates glucose-stimulated insulin secretion in pancreatic beta cells</article-title>
<source/>Diabetologia
          <year>2015</year>
<volume>58</volume>
<fpage>2573</fpage>
<lpage>2581</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-015-3707-4</pub-id>
<pub-id pub-id-type="pmid">26224100</pub-id>
</element-citation>
</ref>
<ref id="B118-cells-08-00255">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shutes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Onesto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Leblond</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Schweighoffer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Der</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases</article-title>
<source/>J. Biol. Chem.
          <year>2007</year>
<volume>282</volume>
<fpage>35666</fpage>
<lpage>35678</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M703571200</pub-id>
<pub-id pub-id-type="pmid">17932039</pub-id>
</element-citation>
</ref>
<ref id="B119-cells-08-00255">
<label>119.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Onesto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shutes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Schweighoffer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Der</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases</article-title>
<source/>Small GTPases in Disease, Part B
          <person-group person-group-type="editor">
<name>
<surname>Balch</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Der</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>A.</given-names>
</name>
</person-group>
<publisher-name>Elsevier Inc.</publisher-name>
<publisher-loc>Amsterdam, The Netherlands</publisher-loc>
<year>2008</year>
<volume>Volume 439</volume>
<fpage>111</fpage>
<lpage>129</lpage>
</element-citation>
</ref>
<ref id="B120-cells-08-00255">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenblatt</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Lyons</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Maiorino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Désiré</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Slingerland</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Burnstein</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer</article-title>
<source/>Endocr. Relat. Cancer
          <year>2011</year>
<volume>18</volume>
<fpage>207</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1677/ERC-10-0049</pub-id>
<pub-id pub-id-type="pmid">21118977</pub-id>
</element-citation>
</ref>
<ref id="B121-cells-08-00255">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Sproul</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Meehan</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Targeting of Rac GTPases blocks the spread of intact human breast cancer</article-title>
<source/>Oncotarget
          <year>2012</year>
<volume>3</volume>
<fpage>608</fpage>
<lpage>619</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.520</pub-id>
<pub-id pub-id-type="pmid">22689141</pub-id>
</element-citation>
</ref>
<ref id="B122-cells-08-00255">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jim Leu</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>T.W.</given-names>
</name>
</person-group>
<article-title>A novel anti-CCN1 monoclonal antibody suppresses Rac-dependent cytoskeletal reorganization and migratory activities in breast cancer cells</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2013</year>
<volume>434</volume>
<fpage>885</fpage>
<lpage>891</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2013.04.045</pub-id>
<pub-id pub-id-type="pmid">23618859</pub-id>
</element-citation>
</ref>
<ref id="B123-cells-08-00255">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niebel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wosnitza</surname>
<given-names>C.I.</given-names>
</name>
<name>
<surname>Famulok</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>RNA-aptamers that modulate the RhoGEF activity of Tiam1</article-title>
<source/>Bioorg. Med. Chem.
          <year>2013</year>
<volume>21</volume>
<fpage>6239</fpage>
<lpage>6246</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2013.05.021</pub-id>
<pub-id pub-id-type="pmid">23757206</pub-id>
</element-citation>
</ref>
<ref id="B124-cells-08-00255">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taniuchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yokotani</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Saibara</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>BART inhibits pancreatic cancer cell invasion by Rac1 inactivation through direct binding to active Rac1</article-title>
<source/>Neoplasia
          <year>2012</year>
<volume>14</volume>
<fpage>440</fpage>
<lpage>450</lpage>
<pub-id pub-id-type="doi">10.1593/neo.12352</pub-id>
<pub-id pub-id-type="pmid">22745590</pub-id>
</element-citation>
</ref>
<ref id="B125-cells-08-00255">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Njardarson</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Gaul</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Danishefsky</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.Y.</given-names>
</name>
</person-group>
<article-title>Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2005</year>
<volume>102</volume>
<fpage>3772</fpage>
<lpage>3776</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0500658102</pub-id>
<pub-id pub-id-type="pmid">15728385</pub-id>
</element-citation>
</ref>
<ref id="B126-cells-08-00255">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dütting</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Heidenreich</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cherpokova</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Ahmadian</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Brakebusch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nieswandt</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Critical off-target effects of the widely used Rac1 inhibitors NSC23766 and EHT1864 in mouse platelets</article-title>
<source/>J. Thromb. Haemost.
          <year>2015</year>
<volume>13</volume>
<fpage>827</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="doi">10.1111/jth.12861</pub-id>
<pub-id pub-id-type="pmid">25628054</pub-id>
</element-citation>
</ref>
<ref id="B127-cells-08-00255">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nan</surname>
<given-names>Q.Z.</given-names>
</name>
</person-group>
<article-title>Activation of Rho GTPase Cdc42 promotes adhesion and invasion in colorectal cancer cells</article-title>
<source/>Med. Sci. Monit. Basic Res.
          <year>2013</year>
<volume>19</volume>
<fpage>201</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.12659/MSMBR.883983</pub-id>
<pub-id pub-id-type="pmid">23884297</pub-id>
</element-citation>
</ref>
<ref id="B128-cells-08-00255">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arias-Romero</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Chernoff</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Targeting Cdc42 in cancer</article-title>
<source/>Expert Opin. Ther. Targets
          <year>2013</year>
<volume>17</volume>
<fpage>1263</fpage>
<lpage>1273</lpage>
<pub-id pub-id-type="doi">10.1517/14728222.2013.828037</pub-id>
<pub-id pub-id-type="pmid">23957315</pub-id>
</element-citation>
</ref>
<ref id="B129-cells-08-00255">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stengel</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Essential role of Cdc42 in Ras-induced transformation revealed by gene targeting</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<elocation-id>e37317</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0037317</pub-id>
<pub-id pub-id-type="pmid">22719838</pub-id>
</element-citation>
</ref>
<ref id="B130-cells-08-00255">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cerione</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation</article-title>
<source/>Cell
          <year>2003</year>
<volume>114</volume>
<fpage>715</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(03)00688-3</pub-id>
<pub-id pub-id-type="pmid">14505571</pub-id>
</element-citation>
</ref>
<ref id="B131-cells-08-00255">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qadir</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Parveen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cdc42: Role in cancer management</article-title>
<source/>Chem. Biol. Drug Des.
          <year>2015</year>
<volume>86</volume>
<fpage>432</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="doi">10.1111/cbdd.12556</pub-id>
<pub-id pub-id-type="pmid">25777055</pub-id>
</element-citation>
</ref>
<ref id="B132-cells-08-00255">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelish</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Salvarezza</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Rodriguez-Boulan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Stamnes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Macia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shair</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Kirchhausen</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro</article-title>
<source/>Nat. Chem. Biol.
          <year>2006</year>
<volume>2</volume>
<fpage>39</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1038/nchembio751</pub-id>
<pub-id pub-id-type="pmid">16408091</pub-id>
</element-citation>
</ref>
<ref id="B133-cells-08-00255">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pelish</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kirchhausen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>G.B.</given-names>
</name>
</person-group>
<article-title>Large scale synthesis of the Cdc42 inhibitor Secramine A and its inhibition of cell spreading</article-title>
<source/>Org. Biomol. Chem.
          <year>2006</year>
<volume>4</volume>
<fpage>4149</fpage>
<lpage>4157</lpage>
<pub-id pub-id-type="doi">10.1039/b609143a</pub-id>
<pub-id pub-id-type="pmid">17312971</pub-id>
</element-citation>
</ref>
<ref id="B134-cells-08-00255">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ambrogio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Voena</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Manazza</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Martinengo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kirchhausen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Inghirami</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chiarle</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation</article-title>
<source/>Cancer Res.
          <year>2008</year>
<volume>68</volume>
<fpage>8899</fpage>
<lpage>8907</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2568</pub-id>
<pub-id pub-id-type="pmid">18974134</pub-id>
</element-citation>
</ref>
<ref id="B135-cells-08-00255">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baltiérrez-Hoyos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Roa-Espitia</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Hernández-González</surname>
<given-names>E.O.</given-names>
</name>
</person-group>
<article-title>The association between CDC42 and caveolin-1 is involved in the regulation of capacitation and acrosome reaction of guinea pig and mouse sperm</article-title>
<source/>Reproduction
          <year>2012</year>
<volume>144</volume>
<fpage>123</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1530/REP-11-0433</pub-id>
<pub-id pub-id-type="pmid">22596063</pub-id>
</element-citation>
</ref>
<ref id="B136-cells-08-00255">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nikolic</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Felts</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Blanchet</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Subramaniam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Piguet</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>HIV-1 activates Cdc42 and induces membrane extensions in immature dendritic cells to facilitate cell-to-cell virus propagation</article-title>
<source/>Blood
          <year>2011</year>
<volume>118</volume>
<fpage>4841</fpage>
<lpage>4852</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2010-09-305417</pub-id>
<pub-id pub-id-type="pmid">21562048</pub-id>
</element-citation>
</ref>
<ref id="B137-cells-08-00255">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lengfeld</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zohlman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salvarezza</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rodriguez-Boulan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Protein kinase C δ regulates the release of collagen type I from vascular smooth muscle cells via regulation of Cdc42</article-title>
<source/>Mol. Biol. Cell
          <year>2012</year>
<volume>23</volume>
<fpage>1955</fpage>
<lpage>1963</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.e11-06-0531</pub-id>
<pub-id pub-id-type="pmid">22456512</pub-id>
</element-citation>
</ref>
<ref id="B138-cells-08-00255">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kenney</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Nöth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Waller</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Strouse</surname>
<given-names>J.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of a Cdc42 protein inhibitor and its use as a molecular probe</article-title>
<source/>J. Biol. Chem.
          <year>2013</year>
<volume>288</volume>
<fpage>8531</fpage>
<lpage>8543</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.435941</pub-id>
<pub-id pub-id-type="pmid">23382385</pub-id>
</element-citation>
</ref>
<ref id="B139-cells-08-00255">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friesland</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2013</year>
<volume>110</volume>
<fpage>1261</fpage>
<lpage>1266</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1116051110</pub-id>
<pub-id pub-id-type="pmid">23284167</pub-id>
</element-citation>
</ref>
<ref id="B140-cells-08-00255">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muhoza</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>Two small molecules, ZCL278 and AZA197 show promise in influencing protein interactions involving the Ras-related protein cell division cycle 42 [Cdc42] to modulate its oncogenic potential</article-title>
<source/>Open J. Biophys.
          <year>2017</year>
<volume>7</volume>
<fpage>71</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.4236/ojbiphy.2017.73006</pub-id>
</element-citation>
</ref>
<ref id="B141-cells-08-00255">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Rac1 and Cdc42 play important roles in arsenic neurotoxicity in primary cultured rat cerebellar astrocytes</article-title>
<source/>Biol. Trace Elem. Res.
          <year>2016</year>
<volume>170</volume>
<fpage>173</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.1007/s12011-015-0456-7</pub-id>
<pub-id pub-id-type="pmid">26231544</pub-id>
</element-citation>
</ref>
<ref id="B142-cells-08-00255">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Neuroglobin plays a protective role in arsenite-induced cytotoxicity by inhibition of Cdc42 and Rac1GTPases in rat cerebellar granule neurons</article-title>
<source/>Cell. Physiol. Biochem.
          <year>2015</year>
<volume>36</volume>
<fpage>1613</fpage>
<lpage>1627</lpage>
<pub-id pub-id-type="doi">10.1159/000430323</pub-id>
<pub-id pub-id-type="pmid">26160017</pub-id>
</element-citation>
</ref>
<ref id="B143-cells-08-00255">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Weninger</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Targeting Rho-GTPases in immune cell migration and inflammation</article-title>
<source/>Br. J. Pharmacol.
          <year>2014</year>
<volume>171</volume>
<fpage>5491</fpage>
<lpage>5506</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12658</pub-id>
<pub-id pub-id-type="pmid">24571448</pub-id>
</element-citation>
</ref>
<ref id="B144-cells-08-00255">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Humphries-Bickley</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Castillo-Pichardo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hernandez-O’Farrill</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Borrero-Garcia</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Forestier-Roman</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gerena</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Blanco</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rivera-Robles</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Rodriguez-Medina</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Cubano</surname>
<given-names>L.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of a dual Rac/Cdc42 inhibitor MBQ-167 in metastatic cancer</article-title>
<source/>Mol. Cancer Ther.
          <year>2017</year>
<volume>16</volume>
<fpage>805</fpage>
<lpage>818</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0442</pub-id>
<pub-id pub-id-type="pmid">28450422</pub-id>
</element-citation>
</ref>
<ref id="B145-cells-08-00255">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zins</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Reichl</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Aharinejad</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e74924</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0074924</pub-id>
<pub-id pub-id-type="pmid">24040362</pub-id>
</element-citation>
</ref>
<ref id="B146-cells-08-00255">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kenney</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rutledge</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Murray-Krezan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Prekeris</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sklar</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>L.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>R-Ketorolac targets Cdc42 and Rac1 and alters ovarian cancer cell behaviors critical for invasion and metastasis</article-title>
<source/>Mol. Cancer Ther.
          <year>2015</year>
<volume>14</volume>
<fpage>2215</fpage>
<lpage>2227</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0419</pub-id>
<pub-id pub-id-type="pmid">26206334</pub-id>
</element-citation>
</ref>
<ref id="B147-cells-08-00255">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dinh-Xuan</surname>
<given-names>A.T.</given-names>
</name>
</person-group>
<article-title>The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review)</article-title>
<source/>Oncol. Lett.
          <year>2014</year>
<volume>8</volume>
<fpage>1907</fpage>
<lpage>1911</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2014.2471</pub-id>
<pub-id pub-id-type="pmid">25289078</pub-id>
</element-citation>
</ref>
<ref id="B148-cells-08-00255">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Marchioni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sipes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Evelyn</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Jerabek-Willemsen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Duhr</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Seibel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wortman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases</article-title>
<source/>Chem. Biol.
          <year>2012</year>
<volume>19</volume>
<fpage>699</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="doi">10.1016/j.chembiol.2012.05.009</pub-id>
<pub-id pub-id-type="pmid">22726684</pub-id>
</element-citation>
</ref>
<ref id="B149-cells-08-00255">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Aksoy</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ryeom</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>Chemotherapy resistance in diffuse type gastric adenocarcinoma is mediated by RhoA activation in cancer stem-like cells</article-title>
<source/>Clin. Cancer Res.
          <year>2016</year>
<volume>22</volume>
<fpage>971</fpage>
<lpage>983</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1356</pub-id>
<pub-id pub-id-type="pmid">26482039</pub-id>
</element-citation>
</ref>
<ref id="B150-cells-08-00255">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Marchioni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Evelyn</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Sipes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Seibel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wortman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2013</year>
<volume>110</volume>
<fpage>3155</fpage>
<lpage>3160</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1212324110</pub-id>
<pub-id pub-id-type="pmid">23382194</pub-id>
</element-citation>
</ref>
<ref id="B151-cells-08-00255">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>Y.R.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Signaling mechanisms of inhibition of phospholipase D activation by CHS-111 in formyl peptide-stimulated neutrophils</article-title>
<source/>Biochem. Pharmacol.
          <year>2011</year>
<volume>81</volume>
<fpage>269</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2010.10.007</pub-id>
<pub-id pub-id-type="pmid">20965153</pub-id>
</element-citation>
</ref>
<ref id="B152-cells-08-00255">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>She</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues</article-title>
<source/>Gene Expr.
          <year>2002</year>
<volume>10</volume>
<fpage>231</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.3727/000000002783992406</pub-id>
<pub-id pub-id-type="pmid">12450215</pub-id>
</element-citation>
</ref>
<ref id="B153-cells-08-00255">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Uzawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shiiba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bukawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yokoe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Seki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tanzawa</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Aberrant expression of RAB1A in human tongue cancer</article-title>
<source/>Br. J. Cancer
          <year>2005</year>
<volume>92</volume>
<fpage>1915</fpage>
<lpage>1921</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6602594</pub-id>
<pub-id pub-id-type="pmid">15870709</pub-id>
</element-citation>
</ref>
<ref id="B154-cells-08-00255">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.H.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Q.S.</given-names>
</name>
</person-group>
<article-title>Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway</article-title>
<source/>Cancer Sci.
          <year>2010</year>
<volume>101</volume>
<fpage>1454</fpage>
<lpage>1462</lpage>
<pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01558.x</pub-id>
<pub-id pub-id-type="pmid">20412119</pub-id>
</element-citation>
</ref>
<ref id="B155-cells-08-00255">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Rab40b upregulation correlates with the prognosis of gastric cancer by promoting migration, invasion, and metastasis</article-title>
<source/>Med. Oncol.
          <year>2015</year>
<volume>32</volume>
<fpage>126</fpage>
<pub-id pub-id-type="doi">10.1007/s12032-015-0562-6</pub-id>
<pub-id pub-id-type="pmid">25790780</pub-id>
</element-citation>
</ref>
<ref id="B156-cells-08-00255">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway</article-title>
<source/>Tumor Biol.
          <year>2016</year>
<volume>37</volume>
<fpage>16005</fpage>
<lpage>16013</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-016-5420-4</pub-id>
<pub-id pub-id-type="pmid">27718127</pub-id>
</element-citation>
</ref>
<ref id="B157-cells-08-00255">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Da Silva</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Marchi</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bijian</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Alobaid</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mlynarek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rogatto</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Hier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kowalski</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Alaoui-Jamali</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Predominant Rab-GTPase amplicons contributing to oral squamous cell carcinoma progression to metastasis</article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>21950</fpage>
<lpage>21963</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.4277</pub-id>
<pub-id pub-id-type="pmid">26110570</pub-id>
</element-citation>
</ref>
<ref id="B158-cells-08-00255">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendrix</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maynard</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pauwels</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Braems</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Denys</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>van den Broecke</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>van Belle</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cocquyt</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gespach</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis</article-title>
<source/>J. Natl. Cancer Inst.
          <year>2010</year>
<volume>102</volume>
<fpage>866</fpage>
<lpage>880</lpage>
<pub-id pub-id-type="doi">10.1093/jnci/djq153</pub-id>
<pub-id pub-id-type="pmid">20484105</pub-id>
</element-citation>
</ref>
<ref id="B159-cells-08-00255">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines</article-title>
<source/>Mol. Cell. Proteom.
          <year>2014</year>
<volume>13</volume>
<fpage>3138</fpage>
<lpage>3151</lpage>
<pub-id pub-id-type="doi">10.1074/mcp.M113.033217</pub-id>
<pub-id pub-id-type="pmid">25096996</pub-id>
</element-citation>
</ref>
<ref id="B160-cells-08-00255">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Recchi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Seabra</surname>
<given-names>M.C.</given-names>
</name>
</person-group>
<article-title>Novel functions for Rab GTPases in multiple aspects of tumour progression</article-title>
<source/>Biochem. Soc. Trans.
          <year>2012</year>
<volume>40</volume>
<fpage>1398</fpage>
<lpage>1403</lpage>
<pub-id pub-id-type="doi">10.1042/BST20120199</pub-id>
<pub-id pub-id-type="pmid">23176488</pub-id>
</element-citation>
</ref>
<ref id="B161-cells-08-00255">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roelofs</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Hulley</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Meijer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ebetino</surname>
<given-names>F.H.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Shipman</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells</article-title>
<source/>Int. J. Cancer
          <year>2006</year>
<volume>119</volume>
<fpage>1254</fpage>
<lpage>1261</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.21977</pub-id>
<pub-id pub-id-type="pmid">16619218</pub-id>
</element-citation>
</ref>
<ref id="B162-cells-08-00255">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kawamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shingyoji</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sekine</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Takiguchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tatsumi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions</article-title>
<source/>Cell Death Dis.
          <year>2014</year>
<volume>5</volume>
<fpage>e1517</fpage>
<pub-id pub-id-type="doi">10.1038/cddis.2014.475</pub-id>
<pub-id pub-id-type="pmid">25393473</pub-id>
</element-citation>
</ref>
<ref id="B163-cells-08-00255">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boissier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Magnetto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Frappart</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cuzin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ebetino</surname>
<given-names>F.H.</given-names>
</name>
<name>
<surname>Delmas</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Clezardin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices</article-title>
<source/>Cancer Res.
          <year>1997</year>
<volume>57</volume>
<fpage>3890</fpage>
<lpage>3894</lpage>
<pub-id pub-id-type="pmid">9307266</pub-id>
</element-citation>
</ref>
<ref id="B164-cells-08-00255">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boissier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ferreras</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peyruchaud</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Magnetto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ebetino</surname>
<given-names>F.H.</given-names>
</name>
<name>
<surname>Colombel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delmas</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Delaissé</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Clézardin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases</article-title>
<source/>Cancer Res.
          <year>2000</year>
<volume>60</volume>
<fpage>2949</fpage>
<lpage>2954</lpage>
<pub-id pub-id-type="doi">10.1080/09297040802385400</pub-id>
<pub-id pub-id-type="pmid">10850442</pub-id>
</element-citation>
</ref>
<ref id="B165-cells-08-00255">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fournier</surname>
<given-names>P.G.J.</given-names>
</name>
<name>
<surname>Daubiné</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lundy</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Ebetino</surname>
<given-names>F.H.</given-names>
</name>
<name>
<surname>Clézardin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition In vivo</article-title>
<source/>Cancer Res.
          <year>2008</year>
<volume>68</volume>
<fpage>8945</fpage>
<lpage>8953</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2195</pub-id>
<pub-id pub-id-type="pmid">18974139</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="cells-08-00255-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Role of small GTPases in human cells. Most small GTPases are implied in the regulation of protein secretion, endocytosis and vesicle trafficking. For instance, Ran-activation gradient controls both the export and import of macromolecules between the nucleus and the cytoplasm. Additionally, Rab1 is responsible for regulation of vesicle trafficking between the endoplasmic reticulum and the Golgi apparatus, whereas Rab6 modulates the reverse transport, as well as through the different Golgi apparatus vesicles. Arf1 is implied in intra-Golgi transport, but also enables the accumulation of fatty acids inside the lipid droplets. Otherwise, Rab5 regulates endosome coating. The control of secretory vesicle formation is mainly mediated by Rab11. The products resulting from phagosome digestion can be carried to Golgi apparatus in a Rab9-dependent process, or return to the extracellular matrix in a Rab11-dependent mechanism. Arf6, which is associated with the plasma membrane when inactive, works as a master regulator of vesicle processes. On the other hand, other small GTPases are involved in the maintenance of cell shape and movement, such as Rac, which promotes the generation of lamellipodia, or Cdc42, which promotes the formation of filopodia. RhoA induces the formation of actin filaments in response to cellular stresses. Otherwise, Ras induces the phosphorylation and activation of MAPK, inducing prosurvival responses, such as cell proliferation and cell cycle progression, as well as limiting prodeath signals, such as apoptosis.</p>
</caption>
<graphic xlink:href="cells-08-00255-g001"></graphic>
</fig>
<fig id="cells-08-00255-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>New strategies to target small GTPases in human cancers. To improve the therapeutic efficacy of inhibitors of small GTPases, new approaches have been developed by different strategies. Red boxes represent the inhibitor of GTPases in each of the strategies. Those include generation of new molecules that can fill the specific GEF binding site in GTPases, disruption of GEF-mediated guanine nucleotide exchange, filling of nucleotide binding pocket of small GTPases, impairing nucleotide attachment, and the stimulation of GAP proteins. Given that most of small GTPases need to be attached to the organelle membrane to exert their actions, the development of novel molecules with the ability to abolish this binding has arisen recently as an innovative strategy to inhibit these molecules. Finally, the development of some drugs that interfere with these could also be great to inhibit small GTPases. A brief table situated next to each section of the graphic indicates the small GTPase inhibitors that work through that mechanism.</p>
</caption>
<graphic xlink:href="cells-08-00255-g002"></graphic>
</fig>
<table-wrap id="cells-08-00255-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">cells-08-00255-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Action of Arf1 inhibitors in cancer treatment.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border:solid thin" valign="middle">Name of the Inhibitor</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Mechanism of Action</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Model</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Global Outcomes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">LM11</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Inhibition of ArfGEF binding to Arf1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Breast cancer cell lines cultured in vitro and breast cancer xenografts in zebrafish</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of cell proliferation, invasion and metastasis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B38-cells-08-00255">38</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Breast adenocarcinoma cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Reduction of cell migration in a dose-dependent manner, cell adhesion to matrix and cell proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B13-cells-08-00255">13</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">Exo2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of ArfGEF activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Prostate cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Suppression of cell proliferation, invasion and migration and induction of programmed cell death through apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B44-cells-08-00255">44</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">BFA</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Hindering of Arf1 and GEF joining</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Anaplastic large cell carcinoma in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Reduction of cell proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B49-cells-08-00255">49</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Lung, colon, melanoma, ovarian, renal, prostate, breast and central nervous system tumors in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Increment of cell death and reduction of their proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B50-cells-08-00255">50</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">Acetylated BFA derivatives</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Hindering of Arf1 and GEF joining</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Esophagus squamous cell carcinoma in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Increment of cell death in a sharper way than BFA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B51-cells-08-00255">51</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Ester derivatives of BFA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Hindering of Arf1 and GEF joining</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Lung, colon, melanoma, ovarian, renal, prostate, breast and central nervous system tumors in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Increment of cell death and reduction of their proliferation in a sharper way than BFA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">[<xref ref-type="bibr" rid="B50-cells-08-00255">50</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">C<sub>15</sub> BFA derivatives</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Hindering of Arf1 and GEF joining</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Lung, colon, ovarian, renal, prostate, breast, leukemia, melanoma and central nervous system tumors in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Increase of cell death, which is stronger than BFA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B52-cells-08-00255">52</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">AMF-26/M-COPA</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Impairment of ArfGEF activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Breast cancer xenografts in vivo</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Induction of complete reversion in the growth of these xenografts</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">[<xref ref-type="bibr" rid="B54-cells-08-00255">54</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Melanoma cells both in vitro and in vivo models</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of angiogenesis, proliferation and tumor growth through the suppression of VEGFR1/2.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B56-cells-08-00255">56</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Neoplastic mast cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Suppression of cell proliferation and resistance to imatinib through the abolishment of Kit signaling</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">[<xref ref-type="bibr" rid="B57-cells-08-00255">57</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">SecinH3</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of ArfGEF binding to Arf1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Breast xenografts in vivo</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Reduction of tumor growth, aggressiveness and metastasis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B63-cells-08-00255">63</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Non-small cell lung cancer cell lines in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell proliferation and reduction of cell resistance to gefitinib</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B64-cells-08-00255">64</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Colorectal cancer models both in vivo and in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Decrease cell proliferation, migration and proliferation through the abolishment of ARNO-dependent signaling</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B65-cells-08-00255">65</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">M69</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Block of ArfGEF activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Acute T cell leukemia cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Disturbance of intracellular adhesion through restructuration of actin skeleton</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">[<xref ref-type="bibr" rid="B67-cells-08-00255">67</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="cells-08-00255-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">cells-08-00255-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Action of Ras inhibitors in cancer treatment.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border:solid thin" valign="middle">Name of the Inhibitor</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Mechanism of Action</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Model</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Global Outcomes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Bisphenol A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Disruption of the binding between Ras and SOS.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Cervical cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Decrease in cell proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">[<xref ref-type="bibr" rid="B73-cells-08-00255">73</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">SCH-53870 derivates</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Disruption of the binding between Ras and SOS.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">NIH3T3 mouse fibroblast in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Decrease in cell proliferation both in normal and KRas-overexpressing cells</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B74-cells-08-00255">74</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">SAH-SOS1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Disruption of the binding between Ras and SOS.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Pancreatic, lung and colon cancer cells cultured in vitro bearing different KRAS mutants</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Decrease in cell proliferation in a dose-dependent manner, independently of the KRAS mutant which bears the cells.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">[<xref ref-type="bibr" rid="B75-cells-08-00255">75</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">SCH-54292</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Hindering of the binding between Ras and SOS</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">NIH3T3 mouse fibroblast in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B78-cells-08-00255">78</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">MCP110</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Inhibition of Raf and Ras-binding</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Colon cancer models both in vivo and in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">Impediment of cell proliferation both in vitro and in vivo and synergy with other chemotherapeutic drugs, such as paclitaxel or vincristine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#CCCCCC" valign="middle">[<xref ref-type="bibr" rid="B88-cells-08-00255">88</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Colon cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Arrest of cell cycle in G<sub>1</sub> phase through the abolishment of cyclin D1 levels</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B87-cells-08-00255">87</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">MCP1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of Raf and Ras binding</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Multiple myeloma cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Reduction of cancer cell growth through the induction of intrinsic apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B87-cells-08-00255">87</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">MCP1 and MCP110</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of Raf and Ras binding</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Multiple cancer cell lines defined by the National Cancer Institute (NCI) (Weinstein et al., 1997)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Reduction of cell proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B87-cells-08-00255">87</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">Enantiomeric iridium(III) metal-based compound</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of Ras and Raf interaction</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Human kidney xenografts in vivo and kidney, breast, lung, prostatic, ovarian, melanoma and erythroleukemic cancer cell lines in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell cancer proliferation and reduction of tumor volume without affecting mice global weight</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B83-cells-08-00255">83</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Sulindac sulfide</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Hindering of Raf activation by Ras</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">NIH3T3 mouse fibroblast in vitro and Saos epithelial cells</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Abolishment of Ras-dependent malignant transformation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B84-cells-08-00255">84</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Brest cancer cells in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of E2-derivated pro-proliferative outcomes</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B85-cells-08-00255">85</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">Sema4D</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Stimulation of Ras-GAP activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Adrenal gland phaeochromocytoma cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Reduction of cell migration through inhibition of β<sub>1</sub> integrin activation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B91-cells-08-00255">91</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Salirasib</td>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of Ras anchorage to cytoplasmic membranes</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Pancreatic cell xenografts in vivo</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of tumor growth dose-dependently and stimulation of gemcitabine antiproliferative effects</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B94-cells-08-00255">94</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Lung cancer models both in vivo and in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of cell proliferation and tumor growth</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B95-cells-08-00255">95</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Hepatocellular carcinoma models both in vivo and in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of cell proliferation through the arrest of cell cycle and the induction of apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B96-cells-08-00255">96</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Pancreatic cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Reduction of cell proliferation through the arrest of cell cycle</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B97-cells-08-00255">97</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Prostate cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Enhancement of Exo2 effects on cell proliferation, migration and invasion.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B44-cells-08-00255">44</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Lung cancer patients</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Common used doses and schedule failed in the inhibition of cell proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B98-cells-08-00255">98</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="cells-08-00255-t003" orientation="portrait" position="float">
<object-id pub-id-type="pii">cells-08-00255-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>Action of Rho and Rab inhibitors in cancer treatment.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border:solid thin" valign="middle">Name of the Inhibitor</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Mechanism of Action</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Model</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Global Outcomes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">NSC23766</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of RacGEF binding to Rac</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Prostate cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Reduction of cell proliferation and their invasive characteristics</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B109-cells-08-00255">109</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Pancreatic cancer cells in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Increase of sensibility to radiotherapy</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B111-cells-08-00255">111</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">NSCLC models both in vitro and in vivo</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of cell proliferation and migration. Increment of cell sensibility to gefitinib.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B110-cells-08-00255">110</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">NSC23766 analogs</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of RacGEF binding to Rac</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">High-metastatic breast cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell proliferation in a sharper way than NSC23766 does</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B112-cells-08-00255">112</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">EHT 1864</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of RacGEF activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Breast cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of cell proliferation stimulated by estrogen signaling</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B120-cells-08-00255">120</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Breast cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Sensitization of cancer cells to tamoxifen</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B120-cells-08-00255">120</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">NIH3T3 mouse fibroblast in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of Rac1-derived malignant cell transformation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B119-cells-08-00255">119</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Breast cancer tumors biopsied from patients’ samples</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Restraining of cell invasion and proliferation through programmed cell death induction</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B121-cells-08-00255">121</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">EHop-016</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of Vav1 and -2 activity and its binding with Rac</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Metastatic breast cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Reduction of cell viability and migration through the inhibition of Rac-derived actin structures</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B113-cells-08-00255">113</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Human and murine leukemic cell models both in vitro and in vivo and patient-derived cells</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Increment of overall survival due to the inhibition of cell growth and survival</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B115-cells-08-00255">115</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Myxofibrosarcoma cell lines cultured in vitro and xenografts tumors cultured in vivo</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell growth through the induction of apoptosis and suppression of the generation of lung metastasis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B116-cells-08-00255">116</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Breast cancer xenografts models with EHop-016 intraperitoneal administration</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Repression of tumor growth, metastasis and angiogenesis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B114-cells-08-00255">114</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">YM1B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Repression of RacGEF binding to Rac</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Breast cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Reduction of cell migration and invasion</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B122-cells-08-00255">122</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">BART</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Repression of RacGEF activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Pancreatic cancer cell lines cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell motility and invasion through the regulation of actin cytoskeleton</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B124-cells-08-00255">124</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Migrastatin analogs</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Repression of Rac activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">High metastatic breast cancer cells in vivo xenograft models</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Blockage of cell migration and metastasis through the inhibition of lamellipodia formation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B125-cells-08-00255">125</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">Secramine A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Repression of Cdc42 shuttling between cytoplasm and cell membrane</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">ALCL cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Repression of cell proliferation through the induction of programmed cell death in ALK-positive cells</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B133-cells-08-00255">133</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">ZCL278</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of ITSN and Cdc42 binding</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Prostate cancer cell lines cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of cell motility and migration mediated by actin filaments</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B139-cells-08-00255">139</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">ML141 or CID2950007</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of GTP binding to Cdc42</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Ovarian cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell motility and invasion without affecting to its viability</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B138-cells-08-00255">138</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">MBQ-167</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of GEF binding to Rac/Cdc42</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Breast cancer cells cultured in vitro and xenografts models in vivo</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Repression of cell migration, metastasis and proliferation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B144-cells-08-00255">144</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">AZA1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Prevention of RacGEF binding to Cdc42/Rac</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Prostatic cancer models both in vivo and in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Decrease in cell proliferation through the induction of apoptosis in vitro. Reduction of tumor growth and improvement of mice survival in vivo</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B145-cells-08-00255">145</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">R-ketorolac</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Inhibition of nucleotide docking</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Ovarian cancer cell lines and primary patient-derived cells in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Reduction in cell proliferation and growth</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B146-cells-08-00255">146</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">Rhosin</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of RhoAGEF binding to RhoA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Breast cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell proliferation, migration and invasion</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B148-cells-08-00255">148</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Diffuse gastric cancer spheroids cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell proliferation, migration and invasion. Sensitization of cells to cisplatin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B149-cells-08-00255">149</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Y16</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Hindering of RhoA and LARG joining</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Breast cancer cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">Reduction of cell proliferation and spheroid formation both alone and in combination with Rhosin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin;background:#D0CECE" valign="middle">[<xref ref-type="bibr" rid="B150-cells-08-00255">150</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" valign="middle">Biphosphonate derivatives</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibits Rab prenylation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Melanoma cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell proliferation through cell cycle arrest in S phase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B161-cells-08-00255">161</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Mesothelioma cells cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Induction of cell apoptosis due to the inhibition of topoisomerase II and Rab6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B162-cells-08-00255">162</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Prostate and breast cancer cell lines cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell adhesion to extracellular matrix</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B163-cells-08-00255">163</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Prostate and breast cancer cell lines cultured in vitro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">Inhibition of cell invasion and metastasis through the repression of MMPs activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;border-right:solid thin" valign="middle">[<xref ref-type="bibr" rid="B164-cells-08-00255">164</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>